Search:
(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Personal Web Page

Field of Study

Pharmacokinetics

Subject of Study

薬物送達システム(DDS)としてのリポソームの応用に関する研究 (liposomes, drug delivery system, targeting) (リポソームの血中での安定性や臓器分布などの体内動態を支配する要因の解明.遺伝子送達ベクターとしてのリポソームの研究.リポソームの経皮吸収製剤への応用.)

Book / Paper

Book:

1. Tatsuhiro Ishida and Hiroshi Kiwada :
腫瘍内微小環境の能動的制御に基づくDDSの開発とがん治療への応用,
CMC Publishing Co.,Ltd., Jun. 2013.
2. Masako Ichihara, Naoto Moriyoshi, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery.,
Springer, Jun. 2012.
(DOI: 10.1007/978-1-62703-140-0_4,   PubMed: 23070762)
3. Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Cationic liposomes and tumour vasculature targeting: a therapeutic approach that has potential for solid tumours.,
Souto, E.B. (Ed.), i-Smithers - Creative Publishing Solutions, Aug. 2011.
4. Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
Breaking the barriers to tumor-targeting via nanocarrier-based drug delivery to the tumor microenvironment.,
Nova Science Publishers, 2010.
5. Jose Mario Barichello, Tatsuhiro Ishida and Hiroshi Kiwada :
Complexation of siRNA and pDNA with cationic liposomes: The important aspects in lipoplex preparation.,
A chapter, Liposomes, Methods Mol. Biol., 2010.
(DOI: 10.1007/978-1-60327-360-2_32,   PubMed: 20072901)
6. Tatsuhiro Ishida and Hiroshi Kiwada :
Synergistic antitumor activity of metronomic dosing chemotherapy in combination with liposomal anticancer drug.,
Nova Science Publishers, Apr. 2009.
7. Tatsuhiro Ishida and Hiroshi Kiwada :
Unexpected reactions by in vivo application of PEGylated liposomes.,
Springer Science + Business Media, New York, USA, 2009.
8. Tatsuhiro Ishida and Hiroshi Kiwada :
第10章医学薬学でのリポソーム応用 1節リポソームと細胞の相互作用,
NTS Inc., Tokyo, Jun. 2005.
9. Tatsuhiro Ishida and Hiroshi Kiwada :
第10章医学薬学でのリポソーム応用 3節長期血中滞留性リポソーム,
NTS Inc., Tokyo, Jun. 2005.
10. Hiroshi Kiwada :
総合製剤学,
NANZANDO Co.,Ltd., Tokyo, Apr. 2000.
11. Hiroshi Kiwada :
有効性の向上とバイオアベイラビリティー,
総合製剤学, 2000.
12. Hiroshi Kiwada :
Adv. Drug Deliv. Rev. (Theme Editor), --- The pharmacokinetics of liposomes for tumor targeting ---,
Sep. 1999.
13. Hiroshi Kiwada :
ライフサイエンスにおけるリポソーム·実験マニュアル,
シュプリンガー·フェアラーク東京, Aug. 1992.
14. Hiroshi Kiwada :
ライフサイエンスにおけるリポソーム 実験マニュアル 寺田弘,吉村哲郎編,
Springer-Verlag, Tokyo, 1992.
15. Hiroshi Kiwada :
生物薬剤学ー最近の進歩 伊賀立二,奥村勝彦編,
(株) 薬業時報社, Tokyo, 1989.
16. C Anthony Hunt, Hiroshi Kiwada, M Reader-Shikorr, K Hirano, J Nakamura, R Abra and H Schreier :
Liposomes:Are they effective drug carriers?Topics in Pharmaceutical Sciences 1983,
1983.

Academic Paper (Judged Full Paper):

1. Hiroyuki Nakamura, Lila Selim Ahmed Ali Abu Amr, Miho Nishio, Masao Tanaka, Hidenori ANDO, Hiroshi Kiwada and Tatsuhiro Ishida :
Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose,
Journal of Controlled Release, Vol.220, 406-413, 2015.
(DOI: 10.1016/j.jconrel.2015.11.002,   PubMed: 26548975,   Elsevier: Scopus)
2. Taro Shimizu, Yu Mima, Yosuke Hashimoto, Masami Ukawa, Hidenori ANDO, Hiroshi Kiwada and Tatsuhiro Ishida :
Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells,
Immunobiology, Vol.220, No.10, 1151-1160, 2015.
(DOI: 10.1016/j.imbio.2015.06.005,   PubMed: 26095176,   Elsevier: Scopus)
3. Munehira Kawanishi, Yosuke Hashimoto, Taro Shimizu, Ikuko Sagawa, Tatsuhiro Ishida and Hiroshi Kiwada :
Comprehensive analysis of PEGylated liposome-asscociated proteins relating to the accelerated blood clearance phenomenon by combination with shotgun analysis and conventional methods,
Biotechnology and Applied Biochemistry, Vol.62, No.4, 547-555, 2015.
(DOI: 10.1002/bab.1291,   PubMed: 25196743,   Elsevier: Scopus)
4. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Hiroshi Kiwada and Tatsuhiro Ishida :
Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein,
Molecular Pharmaceutics, Vol.12, No.7, 2429-2435, 2015.
(DOI: 10.1021/acs.molpharmaceut.5b00144,   PubMed: 26070445,   Elsevier: Scopus)
5. Yosuke Hashimoto, Taro Shimizu, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Relationship between the concentration of anti-polyethylene glycol (PEG) in immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice,
Biological & Pharmaceutical Bulletin, Vol.38, No.3, 417-424, 2015.
(DOI: 10.1248/bpb.b14-00653,   PubMed: 25757923,   CiNii: 1390282679608052736,   Elsevier: Scopus)
6. Takuya Suzuki, Masako Ichihara, Kenji Hyodo, Eiichi Yamamoto, Tatsuhiro Ishida, Hiroshi Kiwada, Hiroshi Kikuchi and Hiroshi Ishihara :
Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin,
International Journal of Pharmaceutics, Vol.476, 205-212, 2014.
(DOI: 10.1016/j.ijpharm.2014.09.047,   PubMed: 25280884,   Elsevier: Scopus)
7. Yosuke Hashimoto, Lila Selim Ahmed Ali Abu Amr, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice,
Journal of Controlled Release, Vol.184, 1-8, 2014.
(DOI: 10.1016/j.jconrel.2014.04.003,   PubMed: 24727075,   Elsevier: Scopus)
8. Yosuke Hashimoto, Yumi Uehara, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production,
Gene Therapy, Vol.21, No.6, 593-598, 2014.
(DOI: 10.1038/gt.2014.32,   PubMed: 24694537,   Elsevier: Scopus)
9. Yosuke Hashimoto, Taro Shimizu, Yu Mima, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs,
Toxicology and Applied Pharmacology, Vol.277, No.1, 30-38, 2014.
(DOI: 10.1016/j.taap.2014.03.002,   PubMed: 24632081,   Elsevier: Scopus)
10. Hiroyuki Nakamura, Yusuke Doi, Lila Selim Ahmed Ali Abu Amr, Ai Nagao, Tatsuhiro Ishida and Hiroshi Kiwada :
Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome,
European Journal of Pharmaceutics and Biopharmaceutics, Vol.87, No.1, 142-151, 2014.
(DOI: 10.1016/j.ejpb.2013.12.007,   PubMed: 24361534,   Elsevier: Scopus)
11. Lila Selim Ahmed Ali Abu Amr, Yumi Uehara, Tatsuhiro Ishida and Hiroshi Kiwada :
Application of polyglycerol-coating to pDNA lipoplex for the evasion of the accelerated blood clearance (ABC) phenomenon in nucleic acid delivery.,
Journal of Pharmaceutical Sciences, Vol.103, No.2, 557-566, 2014.
(DOI: 10.1002/jps.23823,   PubMed: 24347396,   Elsevier: Scopus)
12. Lila Selim Ahmed Ali Abu Amr, Masako Ichihara, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Ex-Vivo/In-Vitro Anti-Polyethylene Glycol (PEG) IgM Production From Murine Splenic B Cells Stimulated by PEGylated Liposome,
Biological & Pharmaceutical Bulletin, Vol.36, No.11, 1842-1848, 2013.
(DOI: 10.1248/bpb.b13-00562,   PubMed: 24189428)
13. Takako Nakashima, N Uematsu, M Shibamori, K Sakurai, Tatsuhiro Ishida and Hiroshi Kiwada :
Establishment of an X-ray irradiation-induced glossitis model in rats: biphasic elevation of proinflammatory cytokines and chemokines,
The Journal of Pharmacology and Experimental Therapeutics, Vol.347, No.3, 660-668, 2013.
(DOI: 10.1124/jpet.113.208405,   PubMed: 24060545)
14. Lila Selim Ahmed Ali Abu Amr, Kousuke Nawata, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration,
International Journal of Pharmaceutics, Vol.456, No.1, 235-242, 2013.
(DOI: 10.1016/j.ijpharm.2013.07.059,   PubMed: 23928149)
15. E Alaaeldin, Lila Selim Ahmed Ali Abu Amr, Naoto Moriyoshi, H Sarahan, A Khaled, Tatsuhiro Ishida and Hiroshi Kiwada :
The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.,
Pharmaceutical Research, Vol.30, No.9, 2344-2354, 2013.
(DOI: 10.1007/s11095-013-1078-4,   PubMed: 23673556)
16. Tatsuhiro Ishida and Hiroshi Kiwada :
Development of siRNA Delivery Strategy by Active Control of Tumor Microenvironment,
Journal of the Pharmaceutical Society of Japan, Vol.133, No.3, 379-386, 2013.
(DOI: 10.1248/yakushi.12-00239-5,   CiNii: 1390001206129003136)
17. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.,
Immunobiology, Vol.218, No.5, 725-732, 2013.
(DOI: 10.1016/j.imbio.2012.08.274,   PubMed: 22995937)
18. K Ichikawa, T Asai, K Shimizu, S Yonezawa, T Urakami, H Miyauchi, H Kawashima, Tatsuhiro Ishida, Hiroshi Kiwada and N Oku :
Suppression of immune response by antigen-decorated liposomes encapsulating model agents: A novel strategy for the treatment of allergy.,
Journal of Controlled Release, Vol.167, No.3, 284-289, 2013.
(DOI: 10.1016/j.jconrel.2013.02.002,   PubMed: 23419947)
19. Ai Nagao, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: Promise for clinical application.,
International Journal of Pharmaceutics, Vol.441, No.1-2, 395-401, 2013.
(DOI: 10.1016/j.ijpharm.2012.11.015,   PubMed: 23174409,   Elsevier: Scopus)
20. Takuya Suzuki, Masako Ichihara, Kenji Hyodo, Eiichi Yamamoto, Tatsuhiro Ishida, Hiroshi Kiwada, Hiroshi Ishihara and Hiroshi Kikuchi :
Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.,
International Journal of Pharmaceutics, Vol.436, No.1-2, 636-643, 2012.
(DOI: 10.1016/j.ijpharm.2012.07.049,   PubMed: 22850293)
21. Lila Selim Ahmed Ali Abu Amr, N Eldin Essam, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.,
International Journal of Pharmaceutics, Vol.438, No.1-2, 176-183, 2012.
(DOI: 10.1016/j.ijpharm.2012.08.030,   PubMed: 22944302)
22. Taro Shimizu, Masako Ichihara, Yasuo Yoshioka, Tatsuhiro Ishida, Shinsaku Nakagawa and Hiroshi Kiwada :
Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response.,
Biological & Pharmaceutical Bulletin, Vol.35, No.8, 1336-1342, 2012.
(DOI: 10.1248/bpb.b12-00276,   PubMed: 22863934,   CiNii: 1390001204632293632)
23. Lila Selim Ahmed Ali Abu Amr, Haruna Matsumoto, Yusuke Doi, Hiroyuki Nakamura, Tatsuhiro Ishida, Hiroshi Kiwada and Hiroshi Kiwada :
Tumor type dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.,
European Journal of Pharmaceutics and Biopharmaceutics, Vol.81, No.3, 524-531, 2012.
(DOI: 10.1016/j.ejpb.2012.04.010,   PubMed: 22554766)
24. Jose Mario Barichello, Shinji Kizuki, Tatsuaki Tagami, Soares Alberto Lira Luiz, Hiroshi Kikuchi, Tatsuhiro Ishida and Hiroshi Kiwada :
Agitation during lipoplex formation harmonizes the interaction of siRNA to cationic liposomes.,
International Journal of Pharmaceutics, Vol.430, No.1-2, 359-365, 2012.
(DOI: 10.1016/j.ijpharm.2012.04.006,   PubMed: 22525078)
25. Tatsuaki Tagami, Lila Selim Ahmed Ali Abu Amr, Mariko Matsunaga, Naoto Moriyoshi, Hiroyuki Nakamura, Kazuya Nakamura, Takuya Suzuki, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model,
Drug Delivery and Translational Research, Vol.2, No.2, 77-86, 2012.
(DOI: 10.1007/s13346-012-0059-1,   Elsevier: Scopus)
26. Lila Selim Ahmed Ali Abu Amr, Tomoko Okada, Yusuke Doi, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: Synergy or antagonism?,
International Journal of Pharmaceutics, Vol.426, 263-270, 2012.
(DOI: 10.1016/j.ijpharm.2012.01.046,   PubMed: 22310465)
27. Tatsuaki Tagami, Takuya Suzuki, Mariko Matsunaga, Kazuya Nakamura, Naoto Moriyoshi, Tatsuhiro Ishida and Hiroshi Kiwada :
Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery.,
International Journal of Pharmaceutics, Vol.422, No.1-2, 280-289, 2012.
(DOI: 10.1016/j.ijpharm.2011.10.059,   PubMed: 22101286)
28. Kazuya Nakamura, Lila Selim Ahmed Ali Abu Amr, Mariko Matsunaga, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.,
Molecular Therapy, Vol.19, No.11, 2040-2047, 2011.
(DOI: 10.1038/mt.2011.174,   PubMed: 21878904)
29. Tatsuaki Tagami, Takuya Suzuki, Kiyomi Hirose, Jose Mario Barichello, Naoshi Yamazaki, Tomohiro Asai, Naoto Oku, Tatsuhiro Ishida and Hiroshi Kiwada :
Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma.,
Drug Delivery and Translational Research, Vol.1, No.4, 277-288, 2011.
(DOI: 10.1007/s13346-011-0025-3)
30. Atsushi Saito, Hiroaki Shimizu, Yusuke Doi, Tatsuhiro Ishida, Miki Fujimura, Takashi Inoue, Hiroshi Kiwada and Teiji Tominaga :
Immunoliposomal drug delivery system targeting lectin-like oxidized low density lipoprotein receptor 1 for carotid plaque lesion in rats.,
Journal of Neurosurgery, Vol.115, No.4, 720-727, 2011.
(DOI: 10.3171/2011.5.JNS10227,   PubMed: 21682565)
31. Jose Mario Barichello, Shinji Kizuki, Tatsuaki Tagami, Tomohiro Asai, Tatsuhiro Ishida, Hiroshi Kikuchi, Naoto Oku and Hiroshi Kiwada :
Agitation during lipoplex formation improves the gene knockdown effect of siRNA.,
International Journal of Pharmaceutics, Vol.410, No.1-2, 153-160, 2011.
(DOI: 10.1016/j.ijpharm.2011.03.001,   PubMed: 21392562)
32. Masako Ichihara, Taro Shimizu, Ami Imoto, Yuki Hashiguchi, Yumi Uehara, Tatsuhiro Ishida and Hiroshi Kiwada :
Anti-PEG IgM response against PEGylated liposomes in mice and rats.,
Pharmaceutics, Vol.3, No.1, 1-11, 2011.
(DOI: 10.3390/pharmaceutics3010001)
33. Tatsuaki Tagami, Yumi Uehara, Naoto Moriyoshi, Tatsuhiro Ishida and Hiroshi Kiwada :
Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA.,
Journal of Controlled Release, Vol.151, No.2, 149-154, 2011.
(DOI: 10.1016/j.jconrel.2010.12.013,   PubMed: 21223988)
34. Yusuke Doi, Tomoko Okada, Haruna Matsumoto, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
Combination therapy of metronomic S-1 dosing with oxaliplatin-containing PEG-coated liposome improves antitumor activity in a murine colorectal tumor model.,
Cancer Science, Vol.101, No.11, 2470-2475, 2010.
(DOI: 10.1111/j.1349-7006.2010.01678.x,   PubMed: 20731663)
35. T Ishihara, T Maeda, H Sakamoto, N Takasaki, M Shigyo, Tatsuhiro Ishida, Hiroshi Kiwada, Y Mizushima and T Mizushima :
Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers.,
Biomacromolecules, Vol.11, No.10, 2700-2706, 2010.
(DOI: 10.1021/bm100754e,   PubMed: 20795699)
36. Y Eto, Y Yoshioka, Tatsuhiro Ishida, X Yao, T Morishige, S Narimatsu, H Mizuguchi, Y Mukai, N Okada, Hiroshi Kiwada and S Nakagawa :
Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer.,
Biological & Pharmaceutical Bulletin, Vol.33, No.9, 1540-1544, 2010.
(DOI: 10.1248/bpb.33.1540,   PubMed: 20823571)
37. Hiroyuki Yamazaki, Masateru Miyake, Naoki Kamada, Toru Nishibayashi, Tadashi Mukai, Masaaki Odomi, Tatsuhiro Ishida and Hiroshi Kiwada :
Co-administration of tacrolimus suppresses pharmacokinetic modulation of multiple subcutaneously administrated human interferon-alpha in beagle dogs.,
Drug Metabolism and Pharmacokinetics, Vol.25, No.2, 149-154, 2010.
(DOI: 10.2133/dmpk.25.149,   PubMed: 20460820)
38. H Koide, T Asai, K Hatanaka, S Akai, T Ishii, E Kenjo, Tatsuhiro Ishida, Hiroshi Kiwada, H Tsukada and N Oku :
T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.,
International Journal of Pharmaceutics, Vol.392, No.1-2, 218-223, 2010.
(DOI: 10.1016/j.ijpharm.2010.03.022,   PubMed: 20227473)
39. Tatsuaki Tagami, Kazuya Nakamura, Taro Shimizu, Naoshi Yamazaki, Tatsuhiro Ishida and Hiroshi Kiwada :
CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes.,
Journal of Controlled Release, Vol.142, No.2, 160-166, 2010.
(DOI: 10.1016/j.jconrel.2009.10.017,   PubMed: 19850094)
40. Lila Selim Ahmed Ali Abu Amr, Yusuke Doi, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.,
Journal of Controlled Release, Vol.142, No.2, 167-173, 2010.
(DOI: 10.1016/j.jconrel.2009.10.020,   PubMed: 19861140)
41. Tsutomu Ishihara, Miho Takeda, Haruka Sakamoto, Ayumi Kimoto, Chisa Kobayashi, Naoko Takasaki, Kanae Yuki, Ken-ichiro Tanaka, Mitsuko Takenaga, Rie Igarashi, Taishi Maeda, Naoki Yamakawa, Yoshinari Okamoto, Masami Otsuka, Tatsuhiro Ishida, Hiroshi Kiwada, Yutaka Mizushima and Tohru Mizushima :
Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles.,
Pharmaceutical Research, Vol.26, No.10, 2270-2279, 2009.
(DOI: 10.1007/s11095-009-9943-x,   PubMed: 19633820)
42. Hiroyuki Yamazaki, Masateru Miyake, Toru Nishibayashi, Tadashi Mukai, Masaaki Odomi, Tatsuhiro Ishida and Hiroshi Kiwada :
Effect of co-administration of tacrolimus on the pharmacokinetics of multiple subcutaneous administered interferon-alpha in rats.,
Pharmaceutical Research, Vol.26, No.8, 1832-1837, 2009.
(DOI: 10.1007/s11095-009-9892-4,   PubMed: 19415469)
43. Tatsuaki Tagami, Kazuya Nakamura, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Effect of siRNA in PEG-coated siRNA-lipoplex on the anti-PEG IgM production.,
Journal of Controlled Release, Vol.137, No.3, 234-240, 2009.
(DOI: 10.1016/j.jconrel.2009.04.006,   PubMed: 19361546)
44. Tatsuhiro Ishida, Emi Shiraga and Hiroshi Kiwada :
Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.,
Journal of Controlled Release, Vol.134, No.3, 194-200, 2009.
(DOI: 10.1016/j.jconrel.2008.11.019,   PubMed: 19095022)
45. Lila Selim Ahmed Ali Abu Amr, Shinji Kizuki, Yusuke Doi, Takuya Suzuki, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.,
Journal of Controlled Release, Vol.137, No.1, 8-14, 2009.
(DOI: 10.1016/j.jconrel.2009.02.023,   PubMed: 19285528)
46. Yoshimasa Isakari, Shinji Sogo, Tatsuhiro Ishida, Takuma Kawakami, Toshihide Ono, Takao Taki and Hiroshi Kiwada :
Gene expression analysis during platelet-like particle production in phorbol myristate acetate-treated MEG-01 cells.,
Biological & Pharmaceutical Bulletin, Vol.32, No.3, 354-358, 2009.
(DOI: 10.1248/bpb.32.354,   PubMed: 19252277)
47. Lila Selim Ahmed Ali Abu Amr, Takuya Suzuki, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.,
Journal of Controlled Release, Vol.134, No.1, 18-25, 2009.
(DOI: 10.1016/j.jconrel.2008.10.018,   PubMed: 19010364)
48. Tatsuaki Tagami, Kiyomi Hirose, Jose Mario Barichello, Tatsuhiro Ishida and Hiroshi Kiwada :
Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes.,
Pharmaceutical Research, Vol.25, No.11, 2497-2504, 2008.
(DOI: 10.1007/s11095-008-9663-7,   PubMed: 18581204)
49. Hiroyuki Koide, Tomohiro Asai, Kentaro Hatanaka, Takeo Urakami, Takayuki Ishii, Eriya Kenjo, Masamichi Nishihara, Masayuki Yokoyama, Tatsuhiro Ishida, Hiroshi Kiwada and Naoto Oku :
Particle size-dependent triggering of accelerated blood clearance phenomenon.,
International Journal of Pharmaceutics, Vol.362, No.1-2, 197-200, 2008.
(DOI: 10.1016/j.ijpharm.2008.06.004,   PubMed: 18586076)
50. Emi Shiraga, Jose Mario Barichello, Tatsuhiro Ishida and Hiroshi Kiwada :
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.,
International Journal of Pharmaceutics, Vol.353, No.1-2, 65-73, 2008.
(DOI: 10.1016/j.ijpharm.2007.11.020,   PubMed: 18155369)
51. Kuniko Matsumura-Takeda, Tatsuhiro Ishida, Shinji Sogo, Yoshimasa Isakari, Takao Taki, Toshiki Sudo and Hiroshi Kiwada :
Lactoferrin inhibits platelet production from human megakaryocytes in vitro.,
Biological & Pharmaceutical Bulletin, Vol.31, No.4, 569-573, 2008.
(DOI: 10.1248/bpb.31.569,   PubMed: 18379042)
52. Tatsuhiro Ishida, Shuntarou Kashima and Hiroshi Kiwada :
The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats.,
Journal of Controlled Release, Vol.126, No.2, 162-165, 2008.
(DOI: 10.1016/j.jconrel.2007.11.009,   PubMed: 18160170)
53. Mario José Barichello, Noriko Yamakawa, Masatoshi Kisyuku, Hiroshi Handa, Taiki Shibata, Tatsuhiro Ishida and Hiroshi Kiwada :
Combined effect of liposomalization and addition of glycerol on the transdermal delivery of isosorbide 5-nitrate in rat skin.,
International Journal of Pharmaceutics, Vol.357, No.1-2, 199-205, 2008.
(DOI: 10.1016/j.ijpharm.2008.01.052,   PubMed: 18343610)
54. T Asai, Y Suzuki, S Matsushita, S Yonezawa, J Yokota, Y Katanasaka, Tatsuhiro Ishida, T Dewa, Hiroshi Kiwada, N Nango and N Oku :
Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown.,
Biochemical and Biophysical Research Communications, Vol.368, No.2, 243-248, 2008.
(DOI: 10.1016/j.bbrc.2008.01.074,   PubMed: 18222171)
55. Tatsuhiro Ishida, Wang Xinyu, Taro Shimizu, Kousuke Nawata and Hiroshi Kiwada :
PEGylated liposomes elicit an anti-PEG IgM response in a T-cells independent manner.,
Journal of Controlled Release, Vol.122, No.3, 349-355, 2007.
(DOI: 10.1016/j.jconrel.2007.05.015,   PubMed: 17610982)
56. Hiroto Hatakeyama, Hidetaka Akita, Emi Ishida, Koichi Hashimoto, Hideo Kobayashi, Takanori Aoki, Junko Yasuda, Kenichi Obata, Hiroshi Kikuchi, Tatsuhiro Ishida, Hiroshi Kiwada and Hideyoshi Harashima :
Tumor targeting of doxorubicin by anti MT1-MMP antibody-modified PEG liposomes.,
International Journal of Pharmaceutics, Vol.342, No.1-2, 194-200, 2007.
(DOI: 10.1016/j.ijpharm.2007.04.037,   PubMed: 17583453)
57. Kazutaka Atobe, Tatsuhiro Ishida, Emi Ishida, Kouichi Hashimoto, Hideo Kobayashi, Jyunko Yasuda, Takanori Aoki, Ken-ichi Obata, Hiroshi Kikuchi, Hidetaka Akita, Tomohiro Asai, Hideyoshi Harashima, Naoto Oku and Hiroshi Kiwada :
In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).,
Biological & Pharmaceutical Bulletin, Vol.30, No.5, 972-978, 2007.
(DOI: 10.1248/bpb.30.972,   PubMed: 17473445)
58. Lap Thi Nguen, Kazutaka Atobe, Mari Jose Barichello, Tatsuhiro Ishida and Hiroshi Kiwada :
Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes.,
Biological & Pharmaceutical Bulletin, Vol.30, No.4, 751-757, 2007.
(DOI: 10.1248/bpb.30.751,   PubMed: 17409515)
59. Tatsuaki Tagami, Mari Jose Barichello, Hiroshi Kikuchi, Tatsuhiro Ishida and Hiroshi Kiwada :
The gene-silencing effect of siRNA in cationic lipoplexes is enhanced by incorporating pDNA in the complex.,
International Journal of Pharmaceutics, Vol.333, No.1-2, 62-69, 2007.
(DOI: 10.1016/j.ijpharm.2006.09.057,   PubMed: 17097247)
60. Xinyu Wang, Tatsuhiro Ishida and Hiroshi Kiwada :
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.,
Journal of Controlled Release, Vol.119, No.2, 236-244, 2007.
(DOI: 10.1016/j.jconrel.2007.02.010,   PubMed: 17399838)
61. Yoshimasa Isakari, Yasuo Harada, Dai Ishikawa, Kuniko Matsumura-Takeda, Shinji Sogo, Tatsuhiro Ishida, Takao Taki and Hiroshi Kiwada :
Efficient gene expression in Megakaryocytic cell line using Nucleofection.,
International Journal of Pharmaceutics, Vol.338, No.1-2, 157-164, 2007.
(DOI: 10.1016/j.ijpharm.2007.01.042,   PubMed: 17331684)
62. Tomotaka Kobayashi, Tatsuhiro Ishida, Yurie Okada, Saori Ise, Hideyoshi Harashima and Hiroshi Kiwada :
Effect of Transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.,
International Journal of Pharmaceutics, Vol.329, No.1-2, 94-102, 2007.
(DOI: 10.1016/j.ijpharm.2006.08.039,   PubMed: 16997518)
63. Tatsuhiro Ishida, Kazutaka Atobe, Xinyu Wang and Hiroshi Kiwada :
Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation and high-dose first injection.,
Journal of Controlled Release, Vol.115, No.3, 251-258, 2006.
(DOI: 10.1016/j.jconrel.2006.08.017,   PubMed: 17045355)
64. Tatsuhiro Ishida, Masako Ichihara, Xinyu Wang and Hiroshi Kiwada :
Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes.,
Journal of Controlled Release, Vol.115, No.3, 243-250, 2006.
(DOI: 10.1016/j.jconrel.2006.08.001,   PubMed: 17011060)
65. Mario Jose Barichello, M. Handa, M. Kisyuku, Taiki Shibata, Tatsuhiro Ishida and Hiroshi Kiwada :
Inducing effect of liposomalization on the transdermal delivery of hydrocortisone: creation of a drug supersaturated state.,
Journal of Controlled Release, Vol.115, No.1, 94-102, 2006.
(DOI: 10.1016/j.jconrel.2006.07.008,   PubMed: 16919352)
66. Foi Dang, Wenhao Li, LiGo Zhang, M Japasini, Tatsuhiro Ishida, Hiroshi Kiwada, N. Kaji, M. Tokeshi and Yoshinobu Baba :
Electrophoretic behavior of plasmid DNA in the presence of various intercalating dyes.,
Journal of Chromatography. A, Vol.1118, No.2, 218-225, 2006.
(DOI: 10.1016/j.chroma.2006.03.120,   PubMed: 16643931)
67. Tatsuhiro Ishida, Masako Ichihara, Xinyu Wang, Kenji Yamamoto, Jyunji Kimura, Eiji Majima and Hiroshi Kiwada :
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes.,
Journal of Controlled Release, Vol.112, No.1, 15-25, 2006.
(DOI: 10.1016/j.jconrel.2006.01.005,   PubMed: 16515818)
68. Tatsuhiro Ishida, Wenhao Liu, Zhung Li and Hiroshi Kiwada :
Stimulatory effect of polyethylene glycol (PEG) on gene expression in mouse liver following hydrodynamics-based transfection.,
The Journal of Gene Medicine, Vol.8, No.3, 324-334, 2006.
(DOI: 10.1002/jgm.850,   PubMed: 16288498)
69. Tatsuhiro Ishida, Yurie Okada, Tomotaka Kobayashi and Hiroshi Kiwada :
Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.,
International Journal of Pharmaceutics, Vol.309, No.1-2, 94-100, 2006.
(DOI: 10.1016/j.ijpharm.2005.11.010,   PubMed: 16364578,   Elsevier: Scopus)
70. Lap Thi Nguyen, Tatsuhiro Ishida and Hiroshi Kiwada :
Gene Expression in Primary Cultured Mouse Hepatocytes with a Cationic Liposomal Vector, TFL-3: Comparison with Rat Hepatocytes,
Biological & Pharmaceutical Bulletin, Vol.28, No.8, 1472-1475, 2005.
(DOI: 10.1248/bpb.28.1472,   PubMed: 16079495)
71. Tatsuhiro Ishida, Masae Harada, Wang Xinyu, Masako Ichihara, Kenji Irimura and Hiroshi Kiwada :
Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes,
Journal of Controlled Release, Vol.105, No.3, 305-317, 2005.
(DOI: 10.1016/j.jconrel.2005.04.003,   PubMed: 15908032)
72. Wang Xinyu, Tatsuhiro Ishida, Masako Ichihara and Hiroshi Kiwada :
Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rat,
Journal of Controlled Release, Vol.104, No.1, 91-102, 2005.
(DOI: 10.1016/j.jconrel.2005.01.008,   PubMed: 15866337)
73. Wenhao Li, Tatsuhiro Ishida, Yurie Okada, Naoto Oku and Hiroshi Kiwada :
Increased Gene Expression by Cationic Liposomes (TFL-3) in Lung Metastases Following Intravenous Injection,
Biological & Pharmaceutical Bulletin, Vol.28, No.4, 701-706, 2005.
(DOI: 10.1248/bpb.28.701,   PubMed: 15802813)
74. Wenhao Li, Tatsuhiro Ishida, Rieko Tachibana, Mohamad Radwan Almofti, Xinyu Wang and Hiroshi Kiwada :
Cell type-specific gene expression, mediated by TFL-3, a cationic liposomal vector, is controlled by a post-transcription process of delivered plasmid DNA,
International Journal of Pharmaceutics, Vol.276, No.1-2, 67-74, 2004.
(DOI: 10.1016/j.ijpharm.2004.02.011,   PubMed: 15113615)
75. Tatsuhiro Ishida, Takako Ichikawa, Masako Ichihara, Yasuyuki Sadzuka and Hiroshi Kiwada :
Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice.,
Journal of Controlled Release, Vol.95, No.3, 403-412, 2004.
(DOI: 10.1016/j.jconrel.2003.12.011,   PubMed: 15023452)
76. Rieko Tachibana, Naoko Ide, Yasuo Shinohara, Hideyoshi Harashima, C. Anthony Hunt and Hiroshi Kiwada :
An assessment of relative transcriptional availability from nonviral vectors,
International Journal of Pharmaceutics, Vol.270, No.1-2, 315-321, 2004.
(DOI: 10.1016/j.ijpharm.2003.10.026,   PubMed: 14726146)
77. Lap Thi Nguyen, Tatsuhiro Ishida, Sachiko Ukitsu, Wen Hao Li, Rieko Tachibana and Hiroshi Kiwada :
Culture Time-Dependent Gene Expression in Isolated Primary Cultured Rat Hepatocytes by Transfection with the Cationic Liposomal Vector TFL-3,
Biological & Pharmaceutical Bulletin, Vol.26, No.6, 880-885, 2003.
(DOI: 10.1248/bpb.26.880,   PubMed: 12808305,   CiNii: 1390282679603298048)
78. Tatsuhiro Ishida, Kaori Masuda, Takako Ichikawa, Masako Ichihara, Kenji Irimura and Hiroshi Kiwada :
Accelerated clearance of a second injection of PEGylated liposomes in mice.,
International Journal of Pharmaceutics, Vol.255, No.1-2, 167-174, 2003.
(DOI: 10.1016/S0378-5173(03)00085-1,   PubMed: 12672612)
79. Mohamad Radwan Almofti, Hideyoshi Harashima, Yasuo Shinohara, Almofti Ammar, Yoshinobu Baba and Hiroshi Kiwada :
Cationic liposome-mediated gene delivery:Biophysical study and mechanism of internalization Arch,
Archives of Biochemistry and Biophysics, Vol.410, No.2, 246-253, 2003.
(DOI: 10.1016/S0003-9861(02)00725-7,   PubMed: 12573284)
80. Tatsuhiro Ishida, Ryuhei Maeda, Masako Ichihara, Kenji Irimura and Hiroshi Kiwada :
Accelerated clearance of PEGylated liposomes in rats after repeated injections.,
Journal of Controlled Release, Vol.88, No.1, 35-42, 2003.
(DOI: 10.1016/S0168-3659(02)00462-5,   PubMed: 12586501)
81. Mohamad Radwan Almofti, Hideyoshi Harashima, Yasuo Shinohara, Ammar Almofti, Wenhao Li and Hiroshi Kiwada :
Lipoplex size determines lipofection efficiency with or without serum.,
Molecular Membrane Biology, Vol.20, No.1, 35-43, 2003.
(DOI: 10.1080/09687680210035104,   PubMed: 12745924)
82. Sayaka Yamamoto, Tatsuhiro Ishida, Akiko Inoue, Junko Mikami, Masahiro Muraguchi, Yasukazu Ohmoto and Hiroshi Kiwada :
HEPC-based liposomes trigger cytokine release from peripheral blood cells: effects of liposomal size, dose and lipid composition,
International Journal of Pharmaceutics, Vol.236, No.1-2, 125-133, 2002.
(DOI: 10.1016/S0378-5173(02)00026-1,   PubMed: 11891076)
83. Rieko Tachibana, Hideyoshi Harashima, Naoko Ide, Sachiko Ukitsu, Yasuko Ohta, Norio Suzuki, Hiroshi Kikuchi, Yasuo Shinohara and Hiroshi Kiwada :
Quantitative Analysis of Correlation between Nunber of Nuclear Plasmids and Gene Expression Activity after Transfection with Cationic Liposomes,
Pharmaceutical Research, Vol.19, No.4, 377-381, 2002.
(PubMed: 12033367)
84. Rieko Tachibana, Hideyoshi Harashima, Tatsuhiro Ishida, Yasuo Shinohara, Mari Hino, Hiroshi Terada, Yoshinobu Baba and Hiroshi Kiwada :
Effect of Cationic Liposomes in an in Vitro Transcription and Translation System,
Biological & Pharmaceutical Bulletin, Vol.25, No.4, 529-531, 2002.
(DOI: 10.1248/bpb.25.529,   PubMed: 11995939)
85. Tatsuhiro Ishida, Yoshihiro Takanashi, Hisako Doi, Isao Yamamoto and Hiroshi Kiwada :
Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stabiliy of the fasudil-loaded liposomes gradient.,
International Journal of Pharmaceutics, Vol.232, No.1-2, 59-67, 2002.
(DOI: 10.1016/S0378-5173(01)00896-1,   PubMed: 11790490,   CiNii: 1570291226801262464)
86. Ryotaro Azuma, Masahito Komuro, Yasuro Kawaguchi, Kazuho Okudaira, Masahiro Hayashi and Hiroshi Kiwada :
Comparative Analysis of In Vitro and In Vivo Pharmacokinetic Parameters Related to Individual Variability of GTS-21 in Canine,
Drug Metabolism and Pharmacokinetics, Vol.17, No.1, 75-82, 2002.
(DOI: 10.2133/dmpk.17.75,   PubMed: 15618655,   Elsevier: Scopus)
87. Ryotaro Azuma, Tomio Hirota, Hiroshi Manabe, Masahito Komuro and Hiroshi Kiwada :
First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference,
European Journal of Pharmaceutical Sciences, Vol.14, No.2, 159-165, 2001.
(DOI: 10.1016/S0928-0987(01)00166-X,   PubMed: 11500261,   Elsevier: Scopus)
88. Tatsuhiro Ishida, Kazumi Yasukawa, Hiroko Kojima, Hideyoshi Harashima and Hiroshi Kiwada :
Effect of cholesterol content in activation of the classical versus the alternative pathway of rat complement system induced by hydrogenated egg phosphatidylcholine-based liposomes,
International Journal of Pharmaceutics, Vol.224, No.1-2, 69-79, 2001.
(DOI: 10.1016/S0378-5173(01)00737-2,   PubMed: 11472816)
89. Tran Minh Huong, Tatsuhiro Ishida, Hideyoshi Harashima and Hiroshi Kiwada :
Species Difference in Correlation between in Vivo/ in Vitro LiposomeComplement Interactions,
Biological & Pharmaceutical Bulletin, Vol.24, No.4, 439-441, 2001.
(DOI: 10.1248/bpb.24.439,   PubMed: 11305612)
90. Yoshihiro Takanashi, Tatsuhiro Ishida, Toshinari Meguro, Hiroshi Kiwada, John H Zhang and Isao Yamamoto :
Efficacy of Intrathecal Liposomal Fasudil for Experimental Cerebral Vasospasm after Subarachnoid Hemorrhage,
Neurosurgery, Vol.48, No.4, 894-901, 2001.
(DOI: 10.1097/00006123-200104000-00041,   PubMed: 11322450)
91. Tran Minh Huong, Tatsuhiro Ishida, Hideyoshi Harashima and Hiroshi Kiwada :
The complement system enhances the clearance of phosphatidylserine (PS)-liposomes in rat and guinea pig,
International Journal of Pharmaceutics, Vol.215, No.1-2, 197-205, 2001.
(DOI: 10.1016/S0378-5173(00)00691-8,   PubMed: 11250105,   Elsevier: Scopus)
92. Tatsuhiro Ishida, Hiroko Kojima, Hideyoshi Harashima and Hiroshi Kiwada :
Biodistribution of liposomes and C3 fragments associated with liposomes:evaluation of their relationship,
International Journal of Pharmaceutics, Vol.205, No.1-2, 183-193, 2000.
(DOI: 10.1016/S0378-5173(00)00511-1,   PubMed: 11000555)
93. Hideyoshi Harashima, Shinya Iida, Yumiko Urakami, Mari Tsuchihashi and Hiroshi Kiwada :
Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling,
Journal of Controlled Release, Vol.61, No.1-2, 93-106, 1999.
(DOI: 10.1016/S0168-3659(99)00110-8,   PubMed: 10469906,   Elsevier: Scopus)
94. Mari Tsuchihashi, Hideyoshi Harashima and Hiroshi Kiwada :
Development of a pharmacokinetic/pharmacodynamic(PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388,
Journal of Controlled Release, Vol.61, No.1-2, 9-19, 1999.
(DOI: 10.1016/S0168-3659(99)00103-0,   PubMed: 10469899,   Elsevier: Scopus)
95. Tran Minh Huong, Hideyoshi Harashima and Hiroshi Kiwada :
In Vivo Studies on the Role of Complement in the Clearance of Liposomes in Rats and Guinea Pigs,
Biological & Pharmaceutical Bulletin, Vol.22, No.5, 515-520, 1999.
(DOI: 10.1248/bpb.22.515,   PubMed: 10375174,   Elsevier: Scopus)
96. Hisao Nemoto, Junya Kikuishi, Shiho Yanagida, Tomoaki Kawano, Mizuki Yamada, Hideyoshi Harasima, Hiroshi Kiwada and Masayuki Shibuya :
Design and synthesis of cholestane derivatives bearing a cascade-type polyol and the effect of their property on a complement system in rat serum,
Bioorganic & Medicinal Chemistry Letters, Vol.9, No.2, 205-208, 1999.
97. 土橋 麻理, 原島 秀吉 and Hiroshi Kiwada :
血中滞留性リポソーム封入ドキソルビシンの腹腔癌における抗腫瘍効果防御システムの構築,
Drug Delivery System, Vol.14, 109-113, 1999.
98. Rieko Tachibana, Hideyoshi Harashima, Masayuki Shono, Makiko Azumano, Mineo Niwa, Siroh Futaki and Hiroshi Kiwada :
Intracellular Regulation of Macromolecules using pH-senstive Liposomes and Nuclear Localization Signal : Qualitative and Quantitative Evaluation of intracellular Trafficking.,
Biochemical and Biophysical Research Communications, Vol.251, No.2, 538-544, 1998.
(DOI: 10.1006/bbrc.1998.9460,   PubMed: 9792809,   Elsevier: Scopus)
99. Tran Minh Huong, Hideyoshi Harashima and Hiroshi Kiwada :
Complement Dependent and Independent Liposome Uptake by Peritoneal Macrophages:Cholesterol Content Dependency,
Biological & Pharmaceutical Bulletin, Vol.21, No.9, 969-973, 1998.
(PubMed: 9781849,   Elsevier: Scopus)
100. Mizuki Yamada, Hideyoshi Harashima and Hiroshi Kiwada :
Kinetic Analysis of the Interaction between Liposomes and the Complement System in Rat Serum:Re-evaluation of Size-Dependency,
Biological & Pharmaceutical Bulletin, Vol.21, No.9, 964-968, 1998.
(DOI: 10.1248/bpb.21.964,   PubMed: 9781848,   Elsevier: Scopus)
101. Naomi Mizuno, Yukio Kato, Kazuhiko Shirota, Yuki Izumi, Tatsuro Irimura, Hideyoshi Harashima, Hiroshi Kiwada, Naomi Motoji, Akiyo Shigematsu and Yuichi Sugiyama :
Mechanism of initial distribution of blood-borne colon carcinoma cells in the liver,
Journal of Hepatology, Vol.28, No.5, 878-885, 1998.
(DOI: 10.1016/S0168-8278(98)80239-0,   PubMed: 9625324,   Elsevier: Scopus)
102. Tatsuhiro Ishida, Shinya Iida, Kouichi Funato and Hiroshi Kiwada :
A novel plasma factor initiating complement activation on cetylmannoside-modified liposomes in human plasma,
International Journal of Pharmaceutics, Vol.164, No.1-2, 91-102, 1998.
(DOI: 10.1016/S0378-5173(97)00403-1)
103. Shicheng Liu, Tatsuhiro Ishida and Hiroshi Kiwada :
Characterization of Bovine Serum Factor Triggering the Lysis of Liposomes via Complement Activation,
Biological & Pharmaceutical Bulletin, Vol.21, No.4, 390-397, 1998.
(DOI: 10.1248/bpb.21.390)
104. 小島 弘子, Tatsuhiro Ishida, 原島 秀吉 and Hiroshi Kiwada :
リポソーム膜中のコレステロール含量が及ぼす補体第3成分(C3)の結合と体内動態への影響,
Drug Delivery System, Vol.13, 55-61, 1998.
105. Tatsuhiro Ishida, Kouichi Funato, Shigeo Kojima, Ritsuko Yoda and Hiroshi Kiwada :
Enhancing effect of cholesterol on the elimination of liposomes from circulation is mediated by complement activation,
International Journal of Pharmaceutics, Vol.156, No.1, 27-37, 1997.
(DOI: 10.1016/S0378-5173(97)00174-9)
106. S Liu, Tatsuhiro Ishida and Hiroshi Kiwada :
Effect of Serum Components from Different Species on Destabilizing Hydrogenated Phosphatidylcholine-Based Liposomes,
Biological & Pharmaceutical Bulletin, Vol.20, No.8, 874-880, 1997.
(DOI: 10.1248/bpb.20.874)
107. Tatsuhiro Ishida, 篠原 美加 and Hiroshi Kiwada :
セチルマンノシド修飾リポソームへのC3フラグメントの結合における粒子径の影響,
Drug Delivery System, Vol.12, No.3, 155-160, 1997.
(DOI: 10.2745/dds.12.155)
108. 浦上 裕美子, 原島 秀吉, 飯田 慎也, 永易 篤 and Hiroshi Kiwada :
リポソームによる抗癌剤の抗腫瘍効果の最適化に関する速度論的研究,
Drug Delivery System, Vol.12, No.6, 403-408, 1997.
(DOI: 10.2745/dds.12.403,   Elsevier: Scopus)
109. 島田 貴浩, 原島 秀吉 and Hiroshi Kiwada :
In vivo実験系による異種リポソーム間の肝取込における競合機構の解明,
薬剤学, Vol.57, No.4, 197-203, 1997.
110. K Yachi, H Harashima, H Kikuchi, R Sudo, H Yamauchi, K Ebihara, H Matsuo, K Funato and Hiroshi Kiwada :
Biopharmaceutical evaluation of the liposomes prepared by rehydration of freeze-dried empty liposomes(FDELs)with an aqueous solution of a drug,
Biopharmaceutics & Drug Disposition, Vol.17, No.7, 589-605, 1996.
(DOI: 10.1002/(SICI)1099-081X(199610)17:7<589::AID-BDD976>3.0.CO;2-D,   PubMed: 8894117,   Elsevier: Scopus)
111. T Yamamoto, M Naito, H Moriyama, H Umezu, H Matsuo, Hiroshi Kiwada and M Arakawa :
Repopulation of murine Kupffer cells after intravenous administration of liposome-encapsulated dichloromethylene diphosphonate,
The American Journal of Pathology, Vol.149, No.4, 1271-1286, 1996.
(PubMed: 8863675)
112. H Harashima, T M Huong, Tatsuhiro Ishida, Y Manabe, H Matsuo and Hiroshi Kiwada :
Synergistic Effect Between Size and Cholesterol Content in the Enhanced Hepatic Uptake Clearance of Liposomes Through Complement Activation in Rats,
Pharmaceutical Research, Vol.13, No.11, 1704-1709, 1996.
(DOI: 10.1023/A:1016401025747)
113. AJ Ferdous, Tatsuhiro Ishida, M Shinohara, H Harashima and Hiroshi Kiwada :
Size-dependent release of carboxyfluorescein from cetylmannoside-modifide liposomes in human plasma,
Biopharmaceutics & Drug Disposition, Vol.17, No.2, 145-154, 1996.
(DOI: 10.1002/(SICI)1099-081X(199603)17:2<145::AID-BDD942>3.0.CO;2-Y)
114. H Harashima, S Komatsu, H Kojima, C Yanagi, Y Morioka, M Naito and Hiroshi Kiwada :
Species difference in the disposition of liposomes among mice, rats, and rabbits: Allometric relationship and species dependent hepatic uptake mechanism,
Pharmaceutical Research, Vol.13, No.7, 1049-1054, 1996.
(DOI: 10.1023/A:1016058724452,   PubMed: 8842043,   Elsevier: Scopus)
115. Atsushi Nagayasu, Kazuko Uchiyama, Tomoyo Nishida, Yumiko Yamagiwa, Yumiko Kawai and Hiroshi Kiwada :
Is control of distribution of liposomes between tumors and bone marrow possible?,
Biochimica et Biophysica Acta (BBA) - Biomembranes, Vol.1278, No.1, 29-34, 1996.
(DOI: 10.1016/0005-2736(95)00188-3,   PubMed: 8611603,   Elsevier: Scopus)
116. 森岡 由美, 原島 秀吉, 吉村 耕二 and Hiroshi Kiwada :
リポソームの細胞内分解過程に及ぼす投与量の影響,
Drug Delivery System, Vol.11, 27-35, 1996.
(Elsevier: Scopus)
117. 内藤 眞, 山本 尚, 梅津 哉, 松尾 浩民 and Hiroshi Kiwada :
リポソーム封入クロドロネートによるKupffer細胞の障害機序,
肝類洞細胞研究の進歩, Vol.8, 89-92, 1996.
118. Kazuko Uchiyama, Atsushi Nagayasu, Yumiko Yamagiwa, Tomoyo Nishida, Hideyoshi Harashima and Hiroshi Kiwada :
Effects of the size and fluidity of liposomes on their accumulation in tumors:A presumption of their interaction with tumors,
International Journal of Pharmaceutics, Vol.121, No.2, 195-203, 1995.
(DOI: 10.1016/0378-5173(95)00015-B,   Elsevier: Scopus)
119. Atsushi Nagayasu, Takashi Shimooka and Hiroshi Kiwada :
Effect of vesicle size on in vivo release of daunorubicin from hydrogenated egg phosphatidylcholine-based liposomes into blood circulation,
Biological & Pharmaceutical Bulletin, Vol.18, No.7, 1020-1023, 1995.
(DOI: 10.1248/bpb.18.1020,   PubMed: 7581243,   Elsevier: Scopus)
120. 永易 篤, 内山 和子, 越智 美代子, 山際 有美子, 武市 陽一郎 and Hiroshi Kiwada :
Effects of Membrane Fluidity on Accumulation of Small Unilamellar Vesicles in Liver and Tumor,
薬剤学, Vol.55, No.2, 81-87, 1995.
(CiNii: 1573668924452460288)
121. Hirotami Matsuo, Chikamasa Yamashita, Kazue Akiyama and Hiroshi Kiwada :
Effect of cetylmannoside modification on the alternative complement pathway activation by liposomes in rat serum,
Biological & Pharmaceutical Bulletin, Vol.18, No.4, 581-585, 1995.
(DOI: 10.1248/bpb.18.581,   PubMed: 7655432,   Elsevier: Scopus)
122. Hideyoshi Harashima, Noriko Hirai and Hiroshi Kiwada :
Kinetic modelling of liposome degradation in peritoneal macrophages,
Biopharmaceutics & Drug Disposition, Vol.16, No.2, 113-123, 1995.
(DOI: 10.1002/bdd.2510160206,   PubMed: 7780045,   Elsevier: Scopus)
123. H Harashima, T Hiraiwa, Y Ochi and Hiroshi Kiwada :
Size dependent liposome degradation in blood:In vivo/in vitro correlation by kinetic modeIing,
Journal of Drug Targeting, Vol.3, No.4, 253-261, 1995.
(DOI: 10.3109/10611869509015954,   PubMed: 8820999,   Elsevier: Scopus)
124. A Nagayasu, T Shimooka and Hiroshi Kiwada :
Solubilization by Triton X-100 makes possible complete recoverery of lipids from liposomes in enzymatic assay,
Biochimica et Biophysica Acta (BBA) - Biomembranes, Vol.1194, No.1, 12-16, 1994.
(DOI: 10.1016/0005-2736(94)90197-X,   PubMed: 8075125,   Elsevier: Scopus)
125. Yoko Matsuki, Rie Bandou, Hiroshi Kiwada, Harumi Maeda and Tsuyoshi Goromaru :
Effects of ascorbic acid on iproniazid-induced hepatitis in phenobarbital-treated rats,
Biological & Pharmaceutical Bulletin, Vol.17, No.8, 1078-1082, 1994.
(DOI: 10.1248/bpb.17.1078,   PubMed: 7820112,   Elsevier: Scopus)
126. Hideyoshi Harashima, Hiroshi Kiwada, Jirou Kajita and Satoshi Kobayashi :
Effects of Benidipine Hydrochloride(Coniel*),a new Calcium Antagonist,on the Cardiac Output,Regional blood Flow and Vascular Resistance in Conscious,Spontaneously Hypertensive Rats,
Biopharmaceutics & Drug Disposition, Vol.15, No.5, 431-438, 1994.
(DOI: 10.1002/bdd.2510150509,   PubMed: 7981431,   Elsevier: Scopus)
127. Atsushi Nagayasu, Takashi Shimooka, Yoshihito Kinouchi, Kazuko Uchiyama, Yoh'ichiro Takeichi and Hiroshi Kiwada :
Effects of Fluidity and Vesicle Size on Antitumor Activity and Myelosuppresive Activity of Liposomes Loaded with Daunorubicin,
Biological & Pharmaceutical Bulletin, Vol.17, No.7, 935-939, 1994.
(DOI: 10.1248/bpb.17.935,   PubMed: 8000381,   Elsevier: Scopus)
128. Sayoko Osaka, Hideki Tsuji and Hiroshi Kiwada :
Uptake of Liposoes Surface-Modified with Glycyrrhizin by Primary Cultured Rat Hepatocytes,
Biological & Pharmaceutical Bulletin, Vol.17, No.7, 940-943, 1994.
(DOI: 10.1248/bpb.17.940,   PubMed: 8000382,   Elsevier: Scopus)
129. H Harashima, Y Ochi and Hiroshi Kiwada :
Kinetic modeling of liposome degradation in serum:Effect of size and concentration of liposomes in vitro,
Biopharmaceutics & Drug Disposition, Vol.15, No.3, 217-225, 1994.
(DOI: 10.1002/bdd.2510150304,   PubMed: 7880982,   Elsevier: Scopus)
130. Hideyoshi Harashima, Kazuya Sakata, Kouichi Funato and Hiroshi Kiwada :
Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes,
Pharmaceutical Research, Vol.11, No.3, 402-406, 1994.
(DOI: 10.1023/A:1018965121222,   PubMed: 8008707,   Elsevier: Scopus)
131. Tatsuhiro Ishida, 篠原 美加, 岩田 房子, 大本 安一 and Hiroshi Kiwada :
抗ヒトC3モノクローナル抗体を用いたリポソーム表面上のC3フラグメント定量,
Drug Delivery System, Vol.9, 25-30, 1994.
(DOI: 10.2745/dds.9.25,   Elsevier: Scopus)
132. Kouiti Funato, Chikamasa Yamashita, Junko Kamada, Sachiko Tominaga and Hiroshi Kiwada :
Plasma Factor Triggering Alternative Complement Pathway Activation by Liposomes,
Pharmaceutical Research, Vol.11, 372-376, 1994.
133. 松木 洋子, Hiroshi Kiwada, 桜井 弘 and 五郎丸 毅 :
ヒドラジン遊離薬物からのフリーラジカルの生成とアスコルビン酸の効果,
磁気共鳴と医学, Vol.5, 109-112, 1994.
134. Hirotami Matsuo, Kouichi Funato, Hideyoshi Harashima and Hiroshi Kiwada :
The Complement- but not Mannos Receptor-Mediated Phagocytosis is Involved in the Hepatic Uptake of Cetylmannoside-Modified Liposomes in Situ,
Journal of Drug Targeting, Vol.2, No.2, 141-146, 1994.
(DOI: 10.3109/10611869409015902,   PubMed: 8069591,   Elsevier: Scopus)
135. 五郎丸 毅, 前田 晴美, 松木 洋子 and Hiroshi Kiwada :
キャピラリーガスクロマトグラフィによるアミノピリンの重水素標識体分離と肝機能評価への応用,
Radioisotopes, Vol.42, No.9, 511-516, 1993.
(DOI: 10.3769/radioisotopes.42.9_511,   CiNii: 1520009410257456128)
136. Hideyoshi Harashima, Yoshihiro Kume, Chizu Yamane and Hiroshi Kiwada :
Kinetic modeling of liposome degradation in blood circulation,
Biopharmaceutics & Drug Disposition, Vol.14, No.3, 265-270, 1993.
(DOI: 10.1002/bdd.2510140309,   PubMed: 8490113,   Elsevier: Scopus)
137. Hideyoshi Harashima, Kazuya Sakata and Hiroshi Kiwada :
Distinction between the depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake of liposomes,
Pharmaceutical Research, Vol.10, No.4, 606-609, 1993.
(DOI: 10.1023/A:1018918623658,   PubMed: 8483847,   Elsevier: Scopus)
138. Hideyoshi Harashima, Yukari Midori, Syunji Ohshima, Kiyoto Yachi, Hiroshi Kikuchi and Hiroshi Kiwada :
Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats(2),
Biopharmaceutics & Drug Disposition, Vol.14, 595-608, 1993.
139. Hideyoshi Harashima, Chizu Yamane, Yoshihiro Kume and Hiroshi Kiwada :
Kinetic analysis of AUC-dependent saturable clearance of liposomes:Mathematical description of AUC dependency,
Journal of Pharmacokinetics and Pharmacodynamics, Vol.21, 299-308, 1993.
140. Hideyoshi Harashima, Yuriko Ohnishi and Hiroshi Kiwada :
In vivo evaluation of the effect of the size and opsonization on the hepatic extraction of liposomes in rats:An application of oldendorf method,
Biopharmaceutics & Drug Disposition, Vol.13, No.7, 549-553, 1992.
(DOI: 10.1002/bdd.2510130708,   PubMed: 1489945,   Elsevier: Scopus)
141. Hideyoshi Harashima, Yoshihiro Kume, Chizu Yamane and Hiroshi Kiwada :
Non-Michaelis-Menten type hepatic uptake of liposomes in the rat,
The Journal of Pharmacy and Pharmacology, Vol.44, No.9, 707-712, 1992.
(DOI: 10.1111/j.2042-7158.1992.tb05504.x,   PubMed: 1360519,   Elsevier: Scopus)
142. 松木 洋子 and Hiroshi Kiwada :
シメチジンのpH変化における物性の安定性,
Medicine and Drug Journal, Vol.28, No.8, 1683-1685, 1992.
143. Hideyoshi Harashima, Syunji Ohshima, Yukari Midori, Kiyoto Yachi, Hiroshi Kikuchi and Hiroshi Kiwada :
Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats:I,
Biopharmaceutics & Drug Disposition, Vol.13, No.3, 155-170, 1992.
(DOI: 10.1002/bdd.2510130302,   PubMed: 1576324,   Elsevier: Scopus)
144. Kouichi Funato, Ritsuko Yoda and Hiroshi Kiwada :
Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma,
Biochimica et Biophysica Acta (BBA) - Biomembranes, Vol.1103, No.2, 198-204, 1992.
(DOI: 10.1016/0005-2736(92)90087-3,   PubMed: 1543704,   Elsevier: Scopus)
145. 山下 親正, 船戸 耕一, 鎌田 順子, 依田 律子 and Hiroshi Kiwada :
マンノース修飾リポソームの安定性に及ぼす種差の影響,
Drug Delivery System, Vol.7, No.3, 165-168, 1992.
(DOI: 10.2745/dds.7.165)
146. 松木 洋子, 本宮 ゆかり, 野田 優子, Hiroshi Kiwada, 桜井 弘 and 五郎丸 毅 :
イプロニアジドの体内動態並びにフリーラジカル中間代謝物に及ぼすアスコルビン酸の影響,
Journal of the Pharmaceutical Society of Japan, Vol.112, No.12, 926-933, 1992.
(DOI: 10.1248/yakushi1947.112.12_926,   Elsevier: Scopus)
147. 松木 洋子, 赤沢 美保, Koichiro Tsuchiya, 桜井 弘, Hiroshi Kiwada and 五郎丸 毅 :
[Effects of ascorbic acid on the free radical formations of isoniazid and its metabolites].,
Journal of the Pharmaceutical Society of Japan, Vol.111, No.10, 600-605, 1991.
(DOI: 10.1248/yakushi1947.111.10_600,   PubMed: 1812280,   Elsevier: Scopus)
148. Chikamasa Yamashita, Saburo Sone, Takeshi Ogura and Hiroshi Kiwada :
Potential Value of Cetylmannoside-modified Liposomes as Carriers of Macrophage Activators to Human Blood Monocytes,
Japanese Journal of Cancer Research, Vol.82, No.5, 569-576, 1991.
(DOI: 10.1111/j.1349-7006.1991.tb01888.x,   PubMed: 1905703,   Elsevier: Scopus)
149. Chikamasa Yamashita, Hirotami Matsuo, Kazue Akiyama and Hiroshi Kiwada :
Enhancing effect of cetylmannoside on targeting of liposomes to Kupffer cells in rats,
International Journal of Pharmaceutics, Vol.70, No.3, 225-233, 1991.
(DOI: 10.1016/0378-5173(91)90286-W,   Elsevier: Scopus)
150. Hideki Tsuji, Sayoko Osaka and Hiroshi Kiwada :
Targeting of lipsomes surface-modified with glycyrrhizin to the liver I Preparation and biological disposition,
Chemical & Pharmaceutical Bulletin, Vol.39, No.4, 1004-1008, 1991.
(PubMed: 1893485,   Elsevier: Scopus)
151. Yoshihiro Kume, Fumiyo Maeda, Hideyoshi Harashima and Hiroshi Kiwada :
Saturable,non-Michaelis-Menten uptake of liposomes by the reticuloendothelial system,
The Journal of Pharmacy and Pharmacology, Vol.43, No.3, 162-166, 1991.
(DOI: 10.1111/j.2042-7158.1991.tb06658.x,   PubMed: 1675271,   Elsevier: Scopus)
152. 久米 義博, 山根 千鶴, 原島 秀吉 and Hiroshi Kiwada :
In vivo実験系における血中でのリポソームの安定性の定量的評価法,
薬物動態, Vol.6, 201-208, 1991.
153. Yoko Matsuki, Yoshimitu Katakuse, Hiroshi Matsuura, Hiroshi Kiwada and Tsuyoshi Goromaru :
Effects of glucose and ascorbic acid on absorption and first pass metabolism of isoniazid in rats,
Chemical & Pharmaceutical Bulletin, Vol.39, 445-448, 1991.
154. 山下 親正, Saburo Sone, 小倉 剛 and Hiroshi Kiwada :
マクロファージコロニー刺激因子含有マンノース修飾リポソームによるヒト単球の生存率増強効果,
Drug Delivery System, Vol.6, No.1, 19-24, 1991.
(DOI: 10.2745/dds.6.19)
155. Koichiro Tahara, Masahiro Hayashi, Shoji Awazu, Yuriko Kato and Hiroshi Kiwada :
Effect of serum on dose- and temperature-dependent hepatic uptake of multilamellar vesicles(MLV),
Journal of Pharmacobio-Dynamics, Vol.12, No.10, 596-601, 1989.
(DOI: 10.1248/bpb1978.12.596,   PubMed: 2630629,   Elsevier: Scopus)
156. Hiroshi Kiwada, Iwao Nakajima, Hiroshi Matsuura, Mitsuko Tsuji and Yuriko Kato :
Application of synthetic alkyl glycoside vesicles as drug carriers 3 Plasma ccomponents affecting stability of the vesicles,
Chemical & Pharmaceutical Bulletin, Vol.36, No.5, 1841-1846, 1988.
(DOI: 10.1248/cpb.36.1841,   PubMed: 3203422,   Elsevier: Scopus)
157. Hiroshi Kiwada, Masami Akimoto, Michiyo Araki, Mitsuko Tsuji and Yuriko Kato :
Application of synthetic liposomes based on acyl amino acids or acyl peptides as drug carriers I.Their preparation and transport of glutathione into the liver,
Chemical & Pharmaceutical Bulletin, Vol.35, No.7, 2935-2942, 1987.
(DOI: 10.1248/cpb.35.2935,   PubMed: 3677244,   Elsevier: Scopus)
158. Hiroshi Kiwada, Takaaki YiYajima and Yuriko Kato :
Studies on the uptake mechanism of liposomes by perfused rat liver 2.An indispensable factor for liver uptake in serum,
Chemical & Pharmaceutical Bulletin, Vol.35, No.3, 1189-1195, 1987.
(DOI: 10.1248/cpb.35.1189,   PubMed: 3607941,   Elsevier: Scopus)
159. Hiroshi Kiwada, Junko Sato, Sunju Yamada and Yuriko Kato :
Feasibility of magnetic liposomes as a Targeting device for drugs,
Chemical & Pharmaceutical Bulletin, Vol.34, No.10, 4253-4258, 1986.
(DOI: 10.1248/cpb.34.4253,   PubMed: 3829157,   Elsevier: Scopus)
160. Hiroshi Kiwada, Sakae Obara, Hiroko Nishiwaki and Yuriko Kato :
Studies on the uptake mechanism of liposomes by perfused rat liver 1.An investigation of effuluent profiles with perfusate containing no blood component,
Chemical & Pharmaceutical Bulletin, Vol.34, No.3, 1249-1256, 1986.
(DOI: 10.1248/cpb.34.1249,   PubMed: 3731343,   Elsevier: Scopus)
161. Yasushi Sato, Hiroshi Kiwada and Yuriko Kato :
Effects of dose and vesicle size on the pharmacokinetics of liposomes,
Chemical & Pharmaceutical Bulletin, Vol.34, 4244-4252, 1986.
162. C Hunt Anthony, R R Burnette, R D MacGregor, A E Strubbe, D T Lau, N Taylor and Hiroshi Kiwada :
Synthesis and evaluation of a prototypal artificial red cell,
Science, Vol.230, No.4730, 1165-1168, 1985.
(DOI: 10.1126/science.4071041,   PubMed: 4071041,   Elsevier: Scopus)
163. Hiroshi Kiwada, Hitoshi Niimura and Yuriko Kato :
Tissue distribution and pharmacokinetic evaluation of targeting efficiency of synthetic alkyl glycoside vesicles,
Chemical & Pharmaceutical Bulletin, Vol.33, No.6, 2475-2482, 1985.
(PubMed: 4064206,   Elsevier: Scopus)
164. Hiroshi Kiwada, Hitoshi Niimura, Yuichi Fujisaki, Sunju Yamada and Yuriko Kato :
Application of synthetic alkyl glycoside vesicles as drug carrier 1.Preparation and physical properties,
Chemical & Pharmaceutical Bulletin, Vol.33, No.2, 753-759, 1985.
(PubMed: 4017121)
165. Hiroshi Kiwada, Hiroyuki Kojima and Yuriko Kato :
Correlation between in vivo and in vitro dissolution rates of(a-bromoisovaleryl)urea polymorphs,
Chemical & Pharmaceutical Bulletin, Vol.32, 3164-3172, 1984.
166. Hiroshi Kiwada, Hiroyuki Kojima and Yuriko Kato :
Pharmacokinetic study on the polymorphs of(a-bromoisovaleryl)urea in rat,
Chemical & Pharmaceutical Bulletin, Vol.31, 1345-1349, 1983.
167. Hiroyuki Kojima, Hitoshi Niimura, Hiroshi Kiwada and Yuriko Kato :
The determination of(a-bromoisovaleryl)urea in plasma and the bioavailability of its polymorphic forms in rat,
Chemical & Pharmaceutical Bulletin, Vol.30, 1831-1836, 1982.
168. Hiroyuki Kojima, Hiroshi Kiwada and Yuriko Kato :
The dissolution properties and physico-chemical properties of polymorphic forms of(a-bromoisovaleryl)urea,
Chemical & Pharmaceutical Bulletin, Vol.30, 1824-1830, 1982.
169. Hiroshi Kiwada, Shoji Awazu and Manabu Hanano :
The study on the biological fate of pasraben at the dose of practical usage in rat 3.The effect of salicylic acid on the fate of paraben.,
Journal of Pharmacobio-Dynamics, Vol.4, No.8, 643-648, 1981.
170. Hiroshi Kiwada, Shoji Awazu and Manabu Hanano :
The study on the biological fate of paraben at the dose of practical usage in rat 2.The pharmacokinetic study on the blood concentration after the administration of ethyl paraben or p-hydroxybenzoic acid.,
Journal of Pharmacobio-Dynamics, Vol.3, No.7, 353-363, 1980.
(PubMed: 7205545)
171. Hiroshi Kiwada, Kazuo Takami and Yuriko Kato :
The preparation and properties of a new polymorphic form of(a-bromoisovaleryl)urea,
Chemical & Pharmaceutical Bulletin, Vol.28, 1351-1356, 1980.
172. Hiroshi Kiwada, Shoji Awazu and Manabu Hanano :
The study on the biological fate of parabens at the dose of practical usage in rat 1.The metabolism and excretion of etyl p-hydroxybenzoate(ethyl paraben)and p-hydroxybenzoic acid,
Journal of Pharmacobio-Dynamics, Vol.2, No.6, 356-364, 1979.
173. Hiroshi Kiwada, Masahiro Hayashi, Tohru Fuwa, Shoji Awazu and Manabu Hanano :
The pharmacokinetic study on the fate of 8-hydroxyquinoline in rat,
Chemical & Pharmaceutical Bulletin, Vol.25, No.7, 1566-1573, 1977.
(PubMed: 409509)
174. Hiroshi Kiwada, Kaname Morita, Masahiro Hayashi, Shoji Awazu and Manabu Hanano :
A New numerical calculation method for deconvolution in linear compartment analysis of pharmacokinetics,
Chemical & Pharmaceutical Bulletin, Vol.25, No.6, 1312-1318, 1977.
(PubMed: 890855)

Review, Commentary:

1. Hiroshi Kiwada :
全身循環性ドラッグキャリアーは可能か?,
生命とくすり, 2,
2. Lila Selim Ahmed Ali Abu Amr, Hiroshi Kiwada and Tatsuhiro Ishida :
Liposomal delivery systems: design optimization and current applications,
Biological & Pharmaceutical Bulletin, Vol.40, No.1, 1-10, Jan. 2017.
(DOI: 10.1248/bpb.b16-00624,   PubMed: 28049940)
3. Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin,
Biological & Pharmaceutical Bulletin, Vol.37, No.2, 206-211, Feb. 2014.
(DOI: 10.1248/bpb.b13-00540,   PubMed: 24492717,   CiNii: 1390282679609960064,   Elsevier: Scopus)
4. Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage,
Journal of Controlled Release, Vol.172, No.1, 38-47, Aug. 2013.
(DOI: 10.1016/j.jconrel.2013.07.026,   PubMed: 23933235)
5. Tatsuhiro Ishida and Hiroshi Kiwada :
Anti-polyethyleneglycol (PEG) antibody response to PEGylated substances.,
Biological & Pharmaceutical Bulletin, Vol.36, No.6, 889-891, Jun. 2013.
(DOI: 10.1248/bpb.b13-00107,   PubMed: 23727911)
6. Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾製剤による抗PEG抗体分泌誘導,
ファルマシア:最前線, Vol.49, No.6, 503-507, Jun. 2013.
7. Tatsuhiro Ishida and Hiroshi Kiwada :
Alteration of tumor microenvironment for improved delivery and intratumor distribution of nanocarriers.,
Biological & Pharmaceutical Bulletin, Vol.36, No.5, 692-697, May 2013.
(DOI: 10.1248/bpb.b13-00121,   PubMed: 23649327)
8. Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソーム製剤繰り返し投与による血中滞留性低下,
C&I Commun., Vol.36, 19-21, 2011.
(CiNii: 1520290884281863808)
9. Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Targeting anticancer drugs to tumor vasculature using cationic liposomes.,
Pharmaceutical Research, Vol.27, No.7, 1171-1183, Mar. 2010.
(DOI: 10.1007/s11095-010-0110-1,   PubMed: 20333455)
10. 小出 裕之, 浅井 知浩, 畑中 剣太朗, 清水 広介, 横山 昌幸, Tatsuhiro Ishida, Hiroshi Kiwada and 奥 直人 :
Elucidation of Accelerated Blood Clearance Phenomenon Caused by Repeat Injection of PEGylated Nanocarriers,
Journal of the Pharmaceutical Society of Japan, Vol.129, No.12, 1445-1451, Dec. 2009.
(DOI: 10.1248/yakushi.129.1445,   CiNii: 1390001206128807680)
11. Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Recent advances in tumor vasculature targeting using liposomal drug delivery systems.,
Expert Opinion on Drug Delivery, Vol.6, No.12, 1297-1309, Dec. 2009.
(DOI: 10.1517/17425240903289928,   PubMed: 19780711)
12. Tatsuhiro Ishida, Tatsuaki Tagami and Hiroshi Kiwada :
siRNA を利用したArgonaute2 遺伝子knockdown によるがん治療法の開発,
和光純薬時報, Vol.77, No.2, 8-11, Apr. 2009.
13. Tatsuhiro Ishida and Hiroshi Kiwada :
Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.,
International Journal of Pharmaceutics, Vol.354, No.1-2, 56-62, Apr. 2008.
(DOI: 10.1016/j.ijpharm.2007.11.005,   PubMed: 18083313)
14. Tatsuhiro Ishida and Hiroshi Kiwada :
Accelerated Blood Clearance (ABC) Phenomenon Induced by Administration of PEGylated Liposome(Symposium Reviews),
Journal of the Pharmaceutical Society of Japan, Vol.128, No.2, 233-243, Feb. 2008.
(DOI: 10.1248/yakushi.128.233,   CiNii: 1390001206127402624)
15. Tatsuhiro Ishida and Hiroshi Kiwada :
ポリマー修飾ナノ微粒子投与による免疫活性化に関する研究,
表面, Vol.45, No.10, 357-371, Oct. 2007.
16. Tatsuhiro Ishida and Hiroshi Kiwada :
リポソームと細胞の相互作用(DDSへの応用),
MEMBRANE, Vol.32, No.1, 18-24, Jan. 2007.
(DOI: 10.5360/membrane.32.18)
17. Tatsuhiro Ishida, Yoshihiro Takanashi and Hiroshi Kiwada :
Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil.,
Biological & Pharmaceutical Bulletin, Vol.29, No.3, 397-402, Mar. 2006.
(DOI: 10.1248/bpb.29.397,   PubMed: 16508135)
18. Tatsuhiro Ishida and Hiroshi Kiwada :
がん治療を目指した機能性リポソームの開発研究,
Chemical Industry, Vol.57, 39-43, 2006.
19. Tatsuhiro Ishida and Hiroshi Kiwada :
Accelerated blood clearance of PEGylated liposomes after repeated injection,
Drug Delivery System, Vol.19, No.6, 495-510, Nov. 2004.
(DOI: 10.2745/dds.19.495,   CiNii: 1390001204640586880)
20. Tatsuhiro Ishida, 高梨 吉裕 and Hiroshi Kiwada :
脳脊髄腔内直接投与可能なDDSの開発とその脳保護効果,
月刊 薬事, Vol.46, No.7, 1333-1338, Jun. 2004.
21. Tatsuhiro Ishida and Hiroshi Kiwada :
DDS研究の現状,
科学フォーラム, 22-28, Dec. 2003.
22. Rieko Tachibana, Shiroh Futaki, Hideyoshi Harashima and Hiroshi Kiwada :
pH-Sensitive Liposomes in Nuclear Targeting of macromolecules,
Methods in Enzymology, Vol.372, 349-361, 2003.
(DOI: 10.1016/S0076-6879(03)72020-5,   PubMed: 14610823,   Elsevier: Scopus)
23. Tatsuhiro Ishida, H Harashima and Hiroshi Kiwada :
Liposome clearance.,
Bioscience Reports, Vol.22, No.2, 197-224, Apr. 2002.
(DOI: 10.1023/a:1020134521778)
24. Hideyoshi Harashima, Tatsuhiro Ishida, Hiroyuki Kamiya and Hiroshi Kiwada :
Pharmacokinetics of Targeting with Liposomes,
Critcal Reviews in Therapeutic Drug Carrier Systems, Vol.19, No.3, 235-275, 2002.
(DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i3.20)
25. Tatsuhiro Ishida, H Harashima and Hiroshi Kiwada :
Interactions of Liposomes with Cells In Vitro and In Vivo:Opsonins and Receptors,
Current drug metabolism, Vol.2, No.4, 397-409, Dec. 2001.
(DOI: 10.2174/1389200013338306)
26. Rieko Tachibana, Hideyoshi Harashima, Yasuo Shinohara and Hiroshi Kiwada :
Quantitative studies on the nuclear transport of plasmid DNA and gene expression employing nonviarl vectors,
Advanced Drug Delivery Reviews, Vol.52, No.3, 219-226, Nov. 2001.
27. Hideyoshi Harashima, Yasuo Shinohara and Hiroshi Kiwada :
Intracellular control of gene trafficking using liposomes as drug carriers,
European Journal of Pharmaceutical Sciences, Vol.13, No.1, 85-89, Apr. 2001.
(DOI: 10.1016/S0928-0987(00)00211-6,   PubMed: 11292572)
28. Rieko Tachibana, Hideyoshi Harashima, Yasuo Shinohara and Hiroshi Kiwada :
Intracellular control of macromolecules by use of liposomes as drug carriers,
Journal of Biological Macromolecules, Vol.1, No.3, 60-67, 2001.
29. 原島 秀吉, 土井 久子, 土橋 麻理 and Hiroshi Kiwada :
血中滞留性リポソームによる抗癌剤の処方設計における最適化,
Drug Delivery System, Vol.15, 442-467, 2000.
30. A Nagayasu, K Uchiyama and Hiroshi Kiwada :
The size of liposomes:Factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs,
Advanced Drug Delivery Reviews, Vol.40, No.1-2, 75-87, Nov. 1999.
(DOI: 10.1016/S0169-409X(99)00041-1,   PubMed: 10837781,   Elsevier: Scopus)
31. H Harashima, M Tsuchihashi, S Iida, H Doi and Hiroshi Kiwada :
Pharmacokinetic/Pharmacodynamic modeling of antitumor agents encapsulated into Liposomes,
Advanced Drug Delivery Reviews, Vol.40, No.1-2, 39-61, Nov. 1999.
(DOI: 10.1016/S0169-409X(99)00039-3,   PubMed: 10837779,   Elsevier: Scopus)
32. Hideyoshi Harashima and Hiroshi Kiwada :
The pharmacokinetics of liposomes in tumor targeting,
Advanced Drug Delivery Reviews, Vol.40, No.1-2, 1-2, Nov. 1999.
(DOI: 10.1016/S0169-409X(99)00036-8,   PubMed: 10837776,   Elsevier: Scopus)
33. Tatsuhiro Ishida and Hiroshi Kiwada :
リポソーム,
色材, Vol.72, 184-191, 1999.
34. 原島 秀吉, Yasuo Shinohara and Hiroshi Kiwada :
キャリアによる細胞内デリバリー戦略と今後の課題,
Drug Delivery System, Vol.14, 157-164, 1999.
35. H Harashima, H Matsuo and Hiroshi Kiwada :
Identification of proteins mediating clearance of liposomes using a liver perfusion system,
Advanced Drug Delivery Reviews, Vol.32, No.1-2, 61-79, Jun. 1998.
(DOI: 10.1016/S0169-409X(97)00132-4,   PubMed: 10837636,   Elsevier: Scopus)
36. Hiroshi Kiwada :
Plasma factors affecting disposition of liposomes,
Advanced Drug Delivery Reviews, Vol.24, No.2-3, 193-199, Mar. 1997.
(DOI: 10.1016/S0169-409X(96)00458-9,   Elsevier: Scopus)
37. Hiroshi Kiwada :
リポソームの体内動態における粒子径認識機構,
Pharm Tech Japan, Vol.13, 233-240, 1997.
38. 原島 秀吉 and Hiroshi Kiwada :
ステルスイムノリポソーム,
綜合臨床, Vol.46, No.9, 2294-2295, 1997.
39. H Harashima and Hiroshi Kiwada :
Liposomal Targeting and Drug Delivery:Kinetic Consideration,
Advanced Drug Delivery Reviews, Vol.19, No.3, 425-444, Jun. 1996.
(DOI: 10.1016/0169-409X(96)00012-9)
40. H Harashima and Hiroshi Kiwada :
Studies on the Mechanism of Uptake of Liposomes Using an Isolated Perfused Liver System,
Journal of Liposome Research, Vol.6, 61-75, 1996.
(DOI: 10.3109/08982109609037202,   Elsevier: Scopus)
41. Hiroshi Kiwada :
リポソームによるDDS,
DDSの進歩1995-96, 44-48, 1995.
42. Hiroshi Kiwada :
リポソームによるDDS,
カレントテラピー, Vol.12, 750-755, 1994.
43. 原島 秀吉 and Hiroshi Kiwada :
リポソームによるDDSの設計,
Biomedica, Vol.8, 374-379, 1993.
44. 山下 親正 and Hiroshi Kiwada :
リポソーム製剤の臨床応用は世界的にどこまで進んでいるか,
Journal of Clinical and Experimental Medicine, Vol.152, 505, 1990.
45. Hiroshi Kiwada :
消化管吸収におけるドラッグデリバリーシステム,
薬局, Vol.39, No.9, 1265-1271, 1988.
46. Hiroshi Kiwada :
リポソームを利用した薬物投与ーより有効なキャリアーシステムへの可能性,
SUT Bulletin, Vol.2, 56-57, 1985.
47. C A Hunt, Hiroshi Kiwada, M Reader-Shikorr, K Hirano, J Nakamura, R Abra and H Schreier :
Liposomes-Are they effective drug carriers?,
Pharm Int, Vol.4, 181, 1983.
48. Hiroshi Kiwada :
リポソーム2ードラッグキャリアーとしてのリポソーム,
細胞工学, Vol.2, 1251-1258, 1983.

Proceeding of International Conference:

1. Taro Shimizu, Yuki Watanabe, Yu Mima, Tatsuhiro Ishida and Hiroshi Kiwada :
Antigen delivery with PEGylated liposome and presentation via MZ-B cells enhanced induction of antigen-specific cytotoxic T lymphocyte,
Liposome Research Days 2014, Copenhagen, Aug. 2014.
2. Munehira Kawanishi, Yosuke Hashimoto, Taro Shimizu, I Sagawa, Tatsuhiro Ishida and Hiroshi Kiwada :
Comprehensive analysis of proteins bound on PEGylated liposome relating to the accelerated blood clearance (ABC) phenomenon by shotgun analysis,
Liposome Research Days 2014, Copenhagen, Aug. 2014.
3. Yukako Fujiwara, Hiroyuki Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
Increased PEG-coated liposomal l-OHP accumulation in the liver relates antitumor effect against M5076 ovarian sarcoma liver metastasis,
Liposome Research Days 2014, Copenhagen, Aug. 2014.
4. Yu Mima, Taro Shimizu, Hiroshi Kiwada and Tatsuhiro Ishida :
Inclusion of ganglioside into PEGylated liposome suppresses the anti-PEG immunity against PEGylated liposome,
Liposome Research Days 2014, Copenhagen, Aug. 2014.
5. Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
Characterization of optimally designed liposomal formulation of Oxaliplatin,
The 41st Annual Meeting & Exposition of the Controlled Release Society, Chicago, Jul. 2014.
6. Noriko Saito-Tarashima, Kojima Takamitsu, Hashimoto Yosuke, Kazuhiro Furukawa, Naoshi Yamazaki, Hiroshi Kiwada, Tatsuhiro Ishida, Noriaki Minakawa and Yoshiharu Takiguchi :
A novel approach of gene suppression using an intelligent shRNA expressing device (iRed),
9th Annual Meeting of the Oligonucleotide Therapeutics Society, Naples(Italy), Oct. 2013.
7. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Potentiation of specific antibody response against antigen encapsulated in PEGylated liposomes via active transport of the liposomes from marginal zone into follicle,
5th Asian Arden Conference, Nagoya, Aug. 2013.
8. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Transport of PEGylated liposomes to follicle induced by pre-stimulation of empty liposomes: Potentiating specific antibody responses against antigen encapsulated in the liposomes,
40th Annual Meeting & Exposition of the Controlled Release Society, Hawaii, Jul. 2013.
9. Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Serum anti-PEG IgM concentration is a determinant factor on hepatic accumulation of PEGylated liposome in the accelerated blood clearance phenomenon,
40th Annual Meeting & Exposition of the Controlled Release Society, Hawaii, Jul. 2013.
10. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Accelerated blood clearance phenomenon upon PEGylated protein,
40th Annual Meeting & Exposition of the Controlled Release Society, Hawaii, Jul. 2013.
11. Miho Nishio, Hiroyuki Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
PEGylated liposomes injected sequentially distribute in different region of solid tumor,
40th Annual Meeting & Exposition of the Controlled Release Society, Hawaii, Jul. 2013.
12. Risako Fujita, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Effect of terminal group of PEG on induction of ABC phenomenon to PEGylated liposome,
40th Annual Meeting & Exposition of the Controlled Release Society, Hawaii, Jul. 2013.
13. Tatsuhiro Ishida and Hiroshi Kiwada :
Improvement of tumor-targeting therapy with nanocarrier system by changing the tumor microenvironment.,
10th DDS Symposium France-Japan, France, Oct. 2012.
14. Tatsuhiro Ishida and Hiroshi Kiwada :
Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model.,
Oligonucleotide Delivery: Biology, Engineering and Development, Austria, Oct. 2012.
15. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Activation of splenic marginal zone B cell by PEGylated liposome with lower dose: triggering transport of antigen-containing second dose PEGylated liposome from marginal zone to follicle,
39th Annual Meeting & Exposition of the Controlled Release Society, Québec City, Jul. 2012.
16. Hiroyuki Nakamura, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
Sequential dose of l-OHP containing PEGylated liposome improve the intratumor delivery and efficacy of PEGylated liposomal anticancer agents.,
39th Annual Meeting & Exposition of the Controlled Release Society, Québec City, Jul. 2012.
17. Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
Anti-PEG IgM response against PEG-coated liposome is further increased by immune stimulation of siRNA via TLR7,,
39th Annual Meeting & Exposition of the Controlled Release Society, Québec City, Jul. 2012.
18. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Contribution of spleen marginal zone B cells on anti-PEG IgM responses against PEGylated liposomes and transport of PEGylated liposomes.,
International Liposome Society 2011 meeting, University of London,, London, Dec. 2011.
19. Naoto Moriyoshi, Mariko Matsunaga, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
Development of new cancer treatment strategy that combines PEG-coated siRNA-lipoplex with metronomic S-1 dosing.,
International Liposome Society 2011 meeting, University of London,, London, Dec. 2011.
20. Tatsuhiro Ishida and Hiroshi Kiwada :
Biological responses against lipid membrane containing PEG.,
3rd International Symposium on Surface and Interface of Biomaterials (SIB2011), Sapporo, Jul. 2011.
21. Tatsuhiro Ishida and Hiroshi Kiwada :
Improvement of tumor-targeting therapy with nanocarrier system by changing the tumor microenviroment,
2011 RCAA International Symposium Endogenous Ligands Modulating Anticancer Agents, Seoul, Feb. 2011.
22. Yuki Hashiguchi, Taro Shimizu, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG on nanocarriers induces anti PEG IgM production as a result of activation of immune system.,
Nano in Cancer: Linking Chemistry, Biology and Clinical Applications in vivo, Miami, Jan. 2011.
23. Tatsuhiro Ishida, Kazuya Nakamura, Yusuke Doi, Naoto Moriyoshi and Hiroshi Kiwada :
A novel double modulation strategy in cancer treatment with chemotherapeutic agent and siRNA: S-1 improves siRNA accumulation and then Bcl-2 knockdown by the siRNA increases chemosensitivity of 5-FU.,
Nano in Cancer: Linking Chemistry, Biology and Clinical Applications in vivo, Miami, Jan. 2011.
24. Yuki Hashiguchi, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Sequential treatment, pre-dose with empty PEGylated liposome (SL) and second dose antigen-encapsulating SL, promotes activation in a primary immune response.,
International Liposome Research Days & Lipids, Liposomes & Membrane Biophysics, Vancouver, Aug. 2010.
25. Haruna Matsumoto, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
Tumor localization and therapeutic effect of PEG-coated liposomal anticancer agent: Tumor type-dependency.,
International Liposome Research Days & Lipids, Liposomes & Membrane Biophysics, Vancouver, Aug. 2010.
26. Tomoko Okada, Yusuke Doi, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Metronomic oral S-1, a fluoropyrimidine anticancer agent, dosing affects tumor accumulation of PEG-coated liposome.,
International Liposome Research Days & Lipids, Liposomes & Membrane Biophysics, Vancouver, Aug. 2010.
27. Mariko Matsunaga, Kazuya Nakamura, Yusuke Doi, Naoto Moriyoshi, Tatsuhiro Ishida and Hiroshi Kiwada :
DEVELOPMENT OF NEW CANCER TREATMENT STRATEGY THAT COMBINES siRNA-LIPOPLEX WITH ORAL TEGAFUR ANTICANCER DRUG S-1.,
International Liposome Research Days & Lipids, Liposomes & Membrane Biophysics, Vancouver, Aug. 2010.
28. Takahiro Iwaki, Tatsuaki Tagami, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
THE EFFECT OF PEGYLATION OF siRNA-LIPOPLEX ON INTRACELLULAR UPTAKE QUANTITY OF SIRNA AND INTRACELLULAR BEHAVIOR OF siRNA.,
International Liposome Research Days & Lipids, Liposomes & Membrane Biophysics, Vancouver, Aug. 2010.
29. Masako Ichihara, Ami Imoto, Yuki Hashiguchi, Yumi Uehara, Tatsuhiro Ishida and Hiroshi Kiwada :
Spleen cells secret anti-PEG IgM following intravenous injection of PEGylated liposome.,
International Liposome Research Days & Lipids, Liposomes & Membrane Biophysics, Vancouver, Aug. 2010.
30. Tatsuhiro Ishida and Hiroshi Kiwada :
Immunostimulatory properties of liposomes containing PEG.,
International Liposome Research Days & Lipids, Liposomes & Membrane Biophysics, Vancouver, Aug. 2010.
31. Yusuke Doi, Tomoko Okada, Haruna Matsumoto, Tatsuhiro Ishida and Hiroshi Kiwada :
Alteration of tumor microenvironment by metronomic S-1 dosing results in augmentation of EPR effect against PEG-coated liposomes.,
4th International Liposome Society Conference. Liposome advances: Progress in Drug and Vaccine Delivery, London, Dec. 2009.
32. Tatsuhiro Ishida, Kazuya Nakamura, Mariko Matsunaga, Yusuke Doi and Hiroshi Kiwada :
A novel double modulation strategy in cancer treatment with chemotherapeutic agent and siRNA: siRNA-induced Bcl-2 knockdown increases chemosensitivity against 5-FU and S-1 improves siRNA accumulation in human colorectal tumor xenograft model.,
4th International Liposome Society Conference. Liposome advances: Progress in Drug and Vaccine Delivery, London, Dec. 2009.
33. H Koide, T Asai, M Yokoyama, Tatsuhiro Ishida, Hiroshi Kiwada and N Oku :
Elucidation of ABC phenomenon caused by repeat injection of PEGylated nanocarrier.,
4th International Liposome Society Conference. Liposome advances: Progress in Drug and Vaccine Delivery, London, Dec. 2009.
34. Tatsuhiro Ishida and Hiroshi Kiwada :
Improvement of tumor-targeting therapy with nanocarriers by changing the tumor microenvironment.,
2009 International Symposium of the Intelligent Drug Delivery System, Seoul, Apr. 2009.
35. Tatsuhiro Ishida, Lila Selim Ahmed Ali Abu Amr, Takuya Suzuki, Yusuke Doi and Hiroshi Kiwada :
Oxaliplatin encapsulated in PEG-coated cationic liposome induces significant tumor growth suppression via dual-targeting approach in murine solid tumor model.,
AACR 100th Annual Meeting 2009, USA, Apr. 2009.
36. Yusuke Doi, Yurie Hira, Tatsuhiro Ishida and Hiroshi Kiwada :
Synergistic antitumor activity of metronomic S-1 dosing in combination with oxaliplatin (1-OHP) containing PEGylated liposome in a murine solid tumor model.,
AACR 100th Annual Meeting 2009, USA, Apr. 2009.
37. Tatsuhiro Ishida and Hiroshi Kiwada :
Improvement of tumor targeting therapy with nanocarriers by changing the tumor microenvironment.,
6th international workshop on Drug Delivery Systems for Nanomedicine, Prague (the Czech Republic), Oct. 2008.
38. Tatsuaki Tagami, Kazuya Nakamura, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Effect of siRNA on anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon when formulated with PEGylated cationic liposome.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
39. Takuya Suzuki, Kazuya Nakamura, Tatsuaki Tagami, Jose Mario Barichello, T Asai, Tatsuhiro Ishida, N Oku and Hiroshi Kiwada :
Anticancer activity of Argonaute2 (Ago2) gene silencing induced by siRNA in mouse tumor xenograft model.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
40. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Interaction of PEGylated liposomes with splenic marginal zone B cells may trigger production of anti-PEG IgM in the ABC phenomenon.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
41. Shinji Kizuki, Jose Mario Barichello, Tatsuaki Tagami, H Kikuchi, Tatsuhiro Ishida and Hiroshi Kiwada :
The impact of novel siRNA-lipoplex preparation method on cellular uptake pathway and gene knockdown efficiency.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
42. Yusuke Doi, Yurie Hira, Tatsuhiro Ishida and Hiroshi Kiwada :
Metronomic dosing of oral anticancer agent affects microenvironment in solid tumor, resulting in enhanced intratumor accumulation and distribution of nanocarrior.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
43. Lila Selim Ahmed Ali Abu Amr, Takuya Suzuki, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin (l-OHP) targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
44. Jose Mario Barichello, Shinji Kizuki, Tatsuaki Tagami, T Asai, Tatsuhiro Ishida, K Hiroshi, N Oku and Hiroshi Kiwada :
Application of vortex-mixing during lipoplex formation affects siRNA-liposome association, siRNA internalization in cells and the RNAi effect.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
45. M Matsushita, (名) Asai, Y Suzuki, Tatsuhiro Ishida, N Maeda, T Dewa, Hiroshi Kiwada, (名) Nango and N Oku :
Antiangiogenic effect by Argonaute2 knockdown used polycation liposome.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
46. Tatsuhiro Ishida and Hiroshi Kiwada :
Improvement of tumor targeting therapy with nanocarriers by changing the tumor microenvironment.,
11th Liposome Research Days conference, Yokohama, Jul. 2008.
47. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Accelerated blood clearance (ABC) phenomenon on PEGylated nanocarrier: Unexpected immune-reaction against PEGylated liposome.,
International Symposium on ``Nanotoxicology Assessment and Biomedical, Environmental Application of Fine Particles and Nanotubes'' (ISNT2008), Sapporo, Jun. 2008.
48. Tatsuhiro Ishida and Hiroshi Kiwada :
Unexpected immunological response against sterically stabilized, PEGylated, liposome after intravenous injection.,
International Symposium on ``Nanotoxicology Assessment and Biomedical, Environmental Application of Fine Particles and Nanotubes'' (ISNT2008), Sapporo, Jun. 2008.
49. Taisuke Matsuo, Naoshi Yamazaki, Tatsuhiro Ishida, Hiroshi Kiwada, Yasuo Shinohara and Masatoshi Kataoka :
Design, preparation and directional insertion of peptides into lipid bilayer membrane and heir application for the preparation of liposome of which surface could be coated by externally added antibody,
International symposium on system cell engineering by multi-scale manipulation, Nagoya, Nov. 2007.
50. H Miyauchi, K Ichikawa, T Urakami, S Yonezawa, K Shimizu, Tatsuhiro Ishida, Hiroshi Kiwada, T Asai and N Oku :
Antigen-conjugated liposomes enhanced hyposensitization immune therapy with extra-low doses.,
34th Annual Meeting & Exposition of the Controlled Release Society, USA, Jul. 2007.
51. T Asai, Y Suzuki, S Matsushita, J Yokota, Tatsuhiro Ishida, Hiroshi Kiwada and N Oku :
Development of antineovascular RNAi cancer therapy targeting to Argonaute 2.,
American Society of Gene Therapy's 10th annual Meeting, Seattle USA, May 2007.
52. Barichello M. Jose, Tatsuhiro Ishida, Soares A. L. Luiz, Shinji Kizuki, Tatsuaki Tagami, Kiyomi Hirose, Hideo Kobayashi, Kouichi Hashimoto, Hiroshi Kikuchi and Hiroshi Kiwada :
Agitation during siRNA-cationic liposomes (CL) complex formation is a key step to improve in vitro RNA interference by lipofection.,
American Society of Gene Therapy's 10th annual Meeting, Seattle USA, May 2007.
53. Tatsuhiro Ishida, Tatsuaki Tagami, Barichello M. Jose, Kiyomi Hirose, Naoshi Yamazaki, Tomohiro Asai, Naoto Oku and Hiroshi Kiwada :
Argonaute2 (Ago2) gene silencing by liposomal transfection with siRNA for Ago2 induces apoptosis on HT1080 cells and HUVECs.,
American Society of Gene Therapy's 10th annual Meeting, Seattle USA, May 2007.
54. Taisuke Matsuo, Naoshi Yamazaki, Tatsuhiro Ishida, Hiroshi Kiwada, Yasuo Shinohara and Masatoshi Kataoka :
Mutant coat proteins of Pf3 bacteriophage as models of membrane proteins and their interactions with lipid bilayer membrane,
Pre-Satellite Meeting of the 3rd Pharmaceutical Sciences World Congress (PSWC 2007) for and by Ph.D. students and postdoctoral fellows, Amsterdam, Apr. 2007.
55. Taisuke Matsuo, Naoshi Yamazaki, Tatsuhiro Ishida, Hiroshi Kiwada, Yasuo Shinohara and Masatoshi Kataoka :
Mutant coat proteins of Pf3 bacteriophage as models of membrane proteins and their interactions with lipid bilayer membrane,
International symposium on system cell engineering by multi-scale manipulation, Nagoya, Nov. 2006.
56. Tatsuhiro Ishida and Hiroshi Kiwada :
Immunological responses to liposome carriers,
The 1st FIP-APSTJ Joint Work Shop on Gene Delivery, Sapporo, Jul. 2006.
57. Tatsuhiro Ishida, Kazutaka Atobe, Wang Xinyu and Hiroshi Kiwada :
The influence of administration of PEGylated liposomal doxorubicin as a first dose on induction of accelerated blood clearance (ABC) phenomenon.,
8th US-Japan symposium on drug delivery systems, Hawaii, Dec. 2005.
58. Tatsuhiro Ishida, Masako Ichihara, Masae Harada, Shuntarou Kashima, Wang Xinyu and Hiroshi Kiwada :
IgM secreted in response to the first injection of PEGylated liposomes involves in induction of the ABC phenomenon.,
31st Annual Meeting and Exposition of the Controlled Release Society., Hawaii, Jun. 2004.
59. Hiroshi Kiwada and Tatsuhiro Ishida :
Immunological responses to nano-drug carriers.,
The 2nd Japan-Korea Joint Symposium on Drug Delivery and Therapy, Kyoto, May 2004.
60. Tatsuhiro Ishida, Masako Ichihara, Shuntarou Kashima, Wang Xinyu and Hiroshi Kiwada :
IgM secreted in response to injection of PEGylated liposomes causes accelerated blood clearance of a subsequent dose.,
9th Liposome Research Days Conference, Hsinchu, Taiwan, May 2004.

Proceeding of Domestic Conference:

1. 飯原 なおみ, 松岡 一郎, Shinji Abe, 宗野 真和, 福山 愛保, Hiroshi Kiwada and 桐野 豊 :
海外の薬学教育(2)― 臨床現場を重視して改革に取り組む,フィンランド・デンマークの薬学教育―,
第2回日本薬学教育学会, Sep. 2017.
2. Taro Shimizu, Yuki Watanabe, Yu Mima, Hiroshi Kiwada and Tatsuhiro Ishida :
脾臓辺縁帯B細胞を標的としたリポソームワクチンの開発,
第25回DDSカンファランス, Sep. 2016.
3. Taro Shimizu, Yuki Watanabe, Yu Mima, Hiroshi Kiwada and Tatsuhiro Ishida :
脾臓辺縁帯B細胞を標的とした新規がんワクチンの開発,
第4回若手研究者シーズ発表会, Nov. 2015.
4. Eri Hondoh, Yu Mima, Hiroshi Kiwada and Tatsuhiro Ishida :
PEG修飾タンパク質Pegasys®投与によるABC現象誘導,
日本薬剤学会第30年会, May 2015.
5. Taro Shimizu, Miho Nishio, Yosuke Hashimoto, 中瀬 博, Hiroshi Kiwada and Tatsuhiro Ishida :
オキサリプラチン封入リポソームの頻回投与が腫瘍免疫系に与える影響,
日本薬学会第135年会, Mar. 2015.
6. Eri Hondoh, Yu Mima, Yosuke Hashimoto, Hiroshi Kiwada and Tatsuhiro Ishida :
PEG修飾タンパク製剤Pegasysに対するABC現象誘導に関する検討,
日本薬学会第135年会, Mar. 2015.
7. Taro Shimizu, Yuki Watanabe, Yu Mima, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームに対する免疫反応を利用した静脈内投与型がんワクチンの開発に関する研究,
第36回生体膜と薬物の相互作用シンポジウム, Nov. 2014.
8. Chihiro Katoh, Lila Selim Ahmed Ali Abu Amr, Hidenori ANDO, Tatsuhiro Ishida and Hiroshi Kiwada :
悪性胸膜中皮腫治療のための核酸搭載カチオニックリポソームの胸腔内投与とその動態評価,
第36回生体膜と薬物の相互作用シンポジウム, Nov. 2014.
9. Yu Mima, Taro Shimizu, Hiroshi Kiwada and Tatsuhiro Ishida :
PEG修飾リポソーム膜へのガングリオシド添加による抗PEG免疫応答の抑制効果,
第36回生体膜と薬物の相互作用シンポジウム, Nov. 2014.
10. Munehira Kawanishi, Yosuke Hashimoto, Taro Shimizu, Hiroshi Kiwada and Tatsuhiro Ishida :
Shotgun分析を用いたPEG修飾リポソーム結合タンパク質の網羅的解析,
第23回DDSカンファランス, Sep. 2014.
11. Ryo Abe, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームの投与経路の違いがanti-PEG IgM分泌に及ぼす影響に関する検討(第2報),
第23回DDSカンファランス, Sep. 2014.
12. Chihiro Katoh, Tatsuhiro Ishida and Hiroshi Kiwada :
In vivo imaging systemによる胸腔内投与リポプレックスの動態評価,
第30回日本DDS学会学術集会, Jul. 2014.
13. Taro Shimizu, Kohsuke Takahashi, Tatsuhiro Ishida and Hiroshi Kiwada :
マウス肺癌細胞に対するFTY720とドキシルとの併用効果に関する検討,
第30回日本DDS学会学術集会, Jul. 2014.
14. Taro Shimizu, Yuki Watanabe, Yu Mima, Tatsuhiro Ishida and Hiroshi Kiwada :
脾臓辺縁帯B細胞による抗原封入PEG修飾リポソームの濾胞への輸送現象を利用した抗腫瘍免疫誘導効果,
日本薬剤学会第29年会, May 2014.
15. Yukako Fujiwara, Hiroyuki Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
転移性肝臓がんの存在がオキサリプラチン封入PEG修飾リポソームの肝移行性へ与える影響,
日本薬学会第134年会, Mar. 2014.
16. Sakiko Kobayashi, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
リポソームからのPemetrexedの放出性が胸腔内移植腫瘍の増殖に与える影響,
日本薬学会第134年会, Mar. 2014.
17. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
Ganglioside添加がPEG修飾リポソームに対する抗PEG IgM分泌に与える影響,
日本薬学会第134年会, Mar. 2014.
18. Taro Shimizu, Yuki Watanabe, Yu Mima, Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームを用いた脾臓濾胞への抗原送達が抗腫瘍免疫誘導に与える影響,
日本薬学会第134年会, Mar. 2014.
19. Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNA搭載PEG修飾リポプレックス投与時に誘導される抗PEG IgM分泌はB細胞に発現するTLR7の活性化により亢進される,
第23回アンチセンスシンポジウム, Nov. 2013.
20. Chihiro Katoh, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
脂質組成の異なるリポソーム胸腔内投与後の体内動態,
第23回アンチセンスシンポジウム, Nov. 2013.
21. Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNA搭載PEG修飾リポプレックス投与時に誘起される抗PEG IgM分泌亢進機構の解明,
第35回生体膜と薬物の相互作用シンポジウム, Nov. 2013.
22. Yuki Watanabe, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソーム前刺激が二回目投与PEG修飾リポソームの脾臓内分布を変化させる,
第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
23. Eri Hondoh, Yu Mima, Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
PEGASYS投与により誘導されるanti-PEG IgMのPEG修飾タンパクに対する反応性,
第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
24. Chihiro Katoh, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
In vivo imaging systemを用いたリポソーム胸腔内投与後の体内動態の評価,
第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
25. Taichi Hasui, Miho Nishio, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin封入PEG修飾リポソーム製剤治療時の腫瘍内遺伝子発現変化の網羅的検討,
第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
26. Tatsuhiro Ishida and Hiroshi Kiwada :
がん治療を指向したDDSの研究開発,
第23回日本医療薬学会年会, Sep. 2013.
27. Miho Nishio, Hiroyuki Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
腫瘍内血管系の動的変化がPEG修飾リポソームの腫瘍内分布に及ぼす影響,
第22回DDSカンファランス, Sep. 2013.
28. Risako Fujita, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾剤末端構造が与えるABC現象誘導への影響に関する検討,
第22回DDSカンファランス, Sep. 2013.
29. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
高用量PEG修飾リポソームによる抗PEG IgMの分泌抑制に関する検討,
第22回DDSカンファランス, Sep. 2013.
30. Yuki Watanabe, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソーム(SL)前刺激により変化する二回目PEG修飾リポソーム(SL)の脾臓内分布の検討,
ナノライフサイエンス・オープンセミナー2013, Sep. 2013.
31. Eri Hondoh, Yu Mima, Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾タンパク投与時に分泌されるanti-PEG IgMによるABC現象の誘導,
ナノライフサイエンス・オープンセミナー2013, Sep. 2013.
32. Chihiro Katoh, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
脂質組成の違いが与える胸腔内投与後のリポソームの体内動態への影響,
ナノライフサイエンス・オープンセミナー2013, Sep. 2013.
33. Taichi Hasui, Miho Nishio, Tatsuhiro Ishida and Hiroshi Kiwada :
マイクロアレイ解析によるOxaliplatin封入PEG修飾リポソーム製剤治療後の腫瘍内遺伝子発現変化の検討,
ナノライフサイエンス・オープンセミナー2013, Aug. 2013.
34. Kohsuke Takahashi, Hiroyuki Nakamura, Miho Nishio, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin封入PEG修飾リポソーム頻回投与による抗腫瘍効果の検討,
ナノライフサイエンス・オープンセミナー2013, Aug. 2013.
35. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
高用量PEG修飾リポソームを用いたABC現象の回避,
第29回日本DDS学会学術集会, Jul. 2013.
36. Chihiro Katoh, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
胸腔内投与後のリポソームの動態に関する研究,
第29回日本DDS学会学術集会, Jul. 2013.
37. Tatsuhiro Ishida and Hiroshi Kiwada :
抗がん剤による腫瘍内微小環境変化を利用した新規DDSの開発,
第29回日本DDS学会学術集会, Jul. 2013.
38. Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNA搭載PEG修飾リポプレックス投与時に惹起される抗PEG IgM分泌応答機構の解明,
日本薬剤学会第28年会, May 2013.
39. Taro Shimizu, Yuki Watanabe, Yu Mima, Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
脾臓辺縁体B細胞によるPEG修飾リポソームの濾胞への輸送現象を利用した特異的抗体誘導効果,
日本薬剤学会第28年会, May 2013.
40. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームを用いた濾胞への抗原送達による抗体誘導効果,
第133年会日本薬学会, Mar. 2013.
41. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾タンパクによるABC現象誘導に関する研究,
第133年会日本薬学会, Mar. 2013.
42. Ami Imoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象を引き起こす抗PEG IgM分泌細胞の特定,
第133年会日本薬学会, Mar. 2013.
43. Risako Fujita, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象誘導へのPEG修飾剤末端構造の影響に関する検討,
第133年会日本薬学会, Mar. 2013.
44. Yuta Seiyama, Yu Mima, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
GangliosideのPEG修飾リポソーム膜への挿入がPEGに対する免疫応答に及ぼす影響,
第133年会日本薬学会, Mar. 2013.
45. Miho Nishio, Hiroyuki Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームの腫瘍内移行に血管系の経時的変化が与える影響,
第133年会日本薬学会, Mar. 2013.
46. Hiroyuki Nakamura, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1とoxaliplatin封入PEG修飾リポソーム併用療法における腫瘍内血管系の変化,
第133年会日本薬学会, Mar. 2013.
47. Ai Nagao, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象がoxaliplatin封入PEG修飾リポソームとS-1併用療法に及ぼす影響に関する研究,
第133年会日本薬学会, Mar. 2013.
48. Mai Arai, Yosuke Hashimoto, 斎藤 陽太, Kazuhiro Furukawa, Tatsuhiro Ishida, Hiroshi Kiwada and Noriaki Minakawa :
新規ハイブリッド型修飾核酸の合成とアンチmiRNA活性の評価,
第133年会日本薬学会, Mar. 2013.
49. Hirotaka Kira, Arisa Yamashita, Naoya Yamanaka, Kazuhiro Furukawa, Tetsuo Yamazaki, Tatsuhiro Ishida, Hiroshi Kiwada and Noriaki Minakawa :
ケミカルツールを用いたsiRNA-タンパク質間の相互作用様式解明,
第133年会日本薬学会, Mar. 2013.
50. Taro Shimizu, Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームの濾胞への輸送現象を利用した免疫誘導に関する検討,
創剤フォーラム第18回若手研究会, Nov. 2012.
51. Naoto Moriyoshi, Tatsuhiro Ishida and Hiroshi Kiwada :
Tegafur製剤S-1とTS標的shRNA含有lipoplexの併用療法による抗腫瘍効果の検討,
創剤フォーラム第18回若手研究会, Nov. 2012.
52. Mizuno Kitagawa, Tatsuhiro Ishida and Hiroshi Kiwada :
細胞内導入後のsiRNA量の経時変化測定におけるreal time PCRの利用に関する検討,
創剤フォーラム第18回若手研究会, Nov. 2012.
53. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
血中anti-PEG IgMがPEG修飾タンパクのクリアランスに与える影響,
創剤フォーラム第18回若手研究会, Nov. 2012.
54. Ami Imoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
抗PEG-IgMを分泌する脾臓B細胞に関する検討,
創剤フォーラム第18回若手研究会, Nov. 2012.
55. Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
Gene knockdown of thymidylate synthase via RNA interference modulates the antitumor efficacy of pemetrexed in malignant mesothelioma xenograft model,
創剤フォーラム第18回若手研究会, Nov. 2012.
56. E Alaaeldin, Lila Selim Ahmed Ali Abu Amr, Hiroyuki Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
Effect of oxaliplatin on anti-PEG IgM and cytokine induced by IV injection of siRNA/PEG-cationic liposome complex.,
創剤フォーラム第18回若手研究会, Nov. 2012.
57. Risako Fujita, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾剤末端構造が与えるanti-PEG IgM分泌誘導への影響に関する検討,
創剤フォーラム第18回若手研究会, Nov. 2012.
58. Yosuke Hashimoto, Risako Fujita, Miho Nishio, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
血中anti-PEG IgM濃度とABC現象発現強度の定量的関係の評価,
創剤フォーラム第18回若手研究会, Nov. 2012.
59. Yuta Seiyama, Yu Mima, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
GangliosideのPEG修飾リポソーム膜への挿入はABC現象を抑制する,
創剤フォーラム第18回若手研究会, Nov. 2012.
60. Ai Nagao, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin封入PEG修飾リポソームとS-1併用療法下におけるaccelerated blood clearance (ABC) 現象に関する検討,
創剤フォーラム第18回若手研究会, Nov. 2012.
61. Miho Nishio, Hiroyuki Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
血管系の変化がPEG修飾リポソームの腫瘍内移行に及ぼす影響,
創剤フォーラム第18回若手研究会, Nov. 2012.
62. Hiroyuki Nakamura, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1とoxaliplatin封入SL併用療法におけるSLの体内動態および腫瘍内環境の変化の評価,
創剤フォーラム第18回若手研究会, Nov. 2012.
63. Yuta Seiyama, Yu Mima, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
ガングリオシドのPEG 修飾リポソーム膜への挿入はPEG に対する自然免疫活性化を抑制する,
第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
64. Yukako Fujiwara, Tatsuhiro Ishida and Hiroshi Kiwada :
オキサリプラチン封入ポリエチレングリコール修飾リポソームの転移性肝がんモデルマウスにおける抗腫瘍効果の検討,
第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
65. Ai Nagao, Tatsuhiro Ishida and Hiroshi Kiwada :
腫瘍皮下移植モデルマウスにおけるS-1 とoxaliplatin 封入PEG 修飾リポソーム併用療法がABC 現象に与える影響の検討,
第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
66. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
血中anti-PEG IgM によるPEG 修飾タンパクのクリアランスに関する検討,
第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
67. Munehira Kawanishi, Taro Shimizu, Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
ショットガン分析によるPEG 修飾リポソームに結合するタンパクの解析,
第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
68. Ryo Abe, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームの投与経路の違いがanti-PEG IgM分泌に及ぼす影響に関する検討,
第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2012.
69. Hirotaka Kira, Naoshi Yamazaki, Tatsuhiro Ishida, Hiroshi Kiwada and Noriaki Minakawa :
ケミカルツールを利用したRNA干渉の発現機構解明,
アンチセンス,遺伝子,デリバリーシンポジウム2012, Sep. 2012.
70. Takamitsu Kojima, Yosuke Hashimoto, Tatsuhiro Ishida, Hiroshi Kiwada and Noriaki Minakawa :
4'-チオDNAを利用した新規RNAi法の開発,
バイオ関連化学シンポジウム, Sep. 2012.
71. Ryo Abe, Taro Shimizu, Yu Mima, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームの投与経路の違いが及ぼすanti-PEG IgM分泌への影響,
ナノライフサイエンス・オープンセミナー2012, Aug. 2012.
72. Munehira Kawanishi, Taro Shimizu, Yosuke Hashimoto, Tatsuhiro Ishida and Hiroshi Kiwada :
ショットガン分析を用いたPEG修飾リポソームに結合する血漿タンパクの解析,
ナノライフサイエンス・オープンセミナー2012, Aug. 2012.
73. Sakiko Kobayashi, Miho Nishio, Hiroyuki Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
Pemetrexed封入PEG修飾リポソームの調整と抗腫瘍効果の検討,
ナノライフサイエンス・オープンセミナー2012, Aug. 2012.
74. Yukako Fujiwara, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
肝転移がんモデルマウスにおけるオキサリプラチン封入ポリエチレングリコール修飾リポソームの体内動態および抗腫瘍効果に関する検討,
ナノライフサイエンス・オープンセミナー2012, Aug. 2012.
75. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
血中anti-PEGIgMがPEG修飾タンパクのクリアランスに与える影響に関する検討,
ナノライフサイエンス・オープンセミナー2012, Aug. 2012.
76. Yu Mima, Yosuke Hashimoto, Taro Shimizu, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
遊離型PEG静脈内投与による抗PEGIgM応答に関する研究,
第28回日本DDS学会学術集会, Jul. 2012.
77. Ai Nagao, Masako Ichihara, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1とl-OHP封入PEG修飾リポソーム併用療法がaccelerated blood clearance(ABC)現象に与える影響の検討,
第28回日本DDS学会学術集会, Jul. 2012.
78. Takuya Suzuki, 兵頭 健治, 山本 栄一, Masako Ichihara, Tatsuhiro Ishida, Hiroshi Kiwada, 石原 比呂之 and 菊池 寛 :
抗がん剤封入PEG修飾リポソームにおけるABC現象(第6報):イヌにおける薬物・脂質投与量とABC現象の関係,
第28回日本DDS学会学術集会, Jul. 2012.
79. Mizuno Kitagawa, Tatsuhiro Ishida and Hiroshi Kiwada :
細胞内導入後のsiRNA量の経時的変化に関する検討,
第28回日本DDS学会学術集会, Jul. 2012.
80. Ami Imoto, Masako Ichihara, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
養子細胞移入法を用いた抗PEG-IgM分泌細胞に関する検討,
第28回日本DDS学会学術集会, Jul. 2012.
81. Taro Shimizu, Ami Imoto, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
脾臓辺縁帯B細胞によるPEG修飾リポソームの輸送機構に関する検討,
第28回日本DDS学会学術集会, Jul. 2012.
82. Masako Ichihara, Taro Shimizu, Ami Imoto, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソーム投与により誘導される抗PEG IgM分泌細胞は脾臓辺縁帯B細胞である,
第28回日本DDS学会学術集会, Jul. 2012.
83. Takuya Suzuki, 兵頭 健治, 山本 栄一, Masako Ichihara, Tatsuhiro Ishida, Hiroshi Kiwada, 石原 比呂之 and 菊池 寛 :
抗がん剤封入PEG修飾リポソームにおけるABC現象(第5報):動物種差,
日本薬剤学会第27年会, May 2012.
84. Masako Ichihara, Taro Shimizu, Ami Imoto, Tatsuhiro Ishida and Hiroshi Kiwada :
脾臓辺縁帯B細胞がABC現象における抗PEG IgM分泌細胞である,
日本薬剤学会第27年会, May 2012.
85. Yosuke Hashimoto, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームの体内動態変動因子anti-PEG IgMの定量評価系の構築,
日本薬剤学会第27年会, May 2012.
86. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
脾臓辺縁帯B細胞によるPEG修飾リポソーム輸送現象を利用した免疫誘導の試み,
日本薬剤学会第27年会, May 2012.
87. Hirotaka Kira, Naoto Moriyoshi, Tatsuhiro Ishida, Hiroshi Kiwada and Noriaki Minakawa :
ケミカルツールを用いたRNA干渉発現の分子認識機構の解明,
日本薬学会第132年会, Mar. 2012.
88. Tomoko Okada, Yusuke Doi, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
フッ化ピリミジン系経口抗癌剤S-1がPEG修飾カチオニックリポソームの腫瘍移行性に与える影響,
日本薬学会第132年会, Mar. 2012.
89. Hiroyuki Nakamura, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1とオキサリプラチン封入PEG修飾リポソームの併用療法におけるリポソームの体内動態の変化に関する検討,
日本薬学会第132年会, Mar. 2012.
90. Tatsuhiro Ishida and Hiroshi Kiwada :
腫瘍内微小環境の能動的制御に基づくsiRNAデリバリー技術の開発とがん治療への展開,
日本薬学会第132年会, Mar. 2012.
91. Takamitsu Kojima, Naoto Moriyoshi, Naoshi Yamazaki, Tatsuhiro Ishida, Hiroshi Kiwada and Noriaki Minakawa :
4'-チオDNAを利用した遺伝子発現抑制法の開発,
日本薬学会第132年会, Mar. 2012.
92. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームと脾臓辺縁帯B 細胞との相互作用に関する検討,
日本薬学会第132年会, Mar. 2012.
93. Takuya Suzuki, 兵頭 健治, 山本 栄一, Masako Ichihara, Tatsuhiro Ishida, Hiroshi Kiwada, 石原 比呂之 and 菊池 寛 :
抗がん剤封入PEG修飾リポソームにおけるaccelerated blood clearance(ABC)現象:種差の検討,
膜シンポジウム2011, Nov. 2011.
94. Yosuke Hashimoto, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象の主要因子であるanti-PEG IgMの定量評価系の確立,
第50回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2011.
95. Risako Fujita, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
Anti-PEG IgM分泌誘導においてPEG修飾剤末端構造が与える影響に関する検討,
第50回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2011.
96. Miho Nishio, Hiroyuki Nakamura, Haruna Matsumoto, Tatsuhiro Ishida and Hiroshi Kiwada :
投与間隔がPEG修飾リポソームの腫瘍内分布に及ぼす影響∼がん種による違いに関する検討∼,
第50回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2011.
97. Hirotaka Kira, 井手 志穂, 新井 真衣, Naoto Moriyoshi, Tatsuhiro Ishida, Hiroshi Kiwada, 松田 彰 and Noriaki Minakawa :
RNA干渉機構解明のためのケミカルツールの合成とその応用,
日本薬学会中国四国支部学術大会, Nov. 2011.
98. Shinji Abe, Dennis Williams, Mami Azuma, Koichiro Tsuchiya, 美妃 山下, 麻衣子 町田 and Hiroshi Kiwada :
日米の薬学部学生間におけるビデオ会議システムを用いた症例検討カンファレンス実施の試み,
日本医療薬学会第21回年会, Oct. 2011.
99. Mami Azuma, Mayumi Sugimura, Chieko Okumura, Shinji Abe and Hiroshi Kiwada :
徳島大学薬学部長期薬局実務実習初年度連携指導体制の検証と課題,
第21回 日本医療薬学会年会, Oct. 2011.
100. Tomoko Okada, Yusuke Doi, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
フッ化ピリミジン系経口抗癌剤がPEG修飾カチオニックリポソームの腫瘍移行性に与える影響,
第20回DDSカンファランス, Sep. 2011.
101. Haruna Matsumoto, Yusuke Doi, Hiroyuki Nakamura, Miho Nishio, Tatsuhiro Ishida, 原田 雅史 and Hiroshi Kiwada :
PEG修飾リポソームの腫瘍内分布領域可視化の試み,
第20回DDSカンファランス, Sep. 2011.
102. Naoto Moriyoshi, Kazuya Nakamura, 松永 真理子, Tatsuhiro Ishida and Hiroshi Kiwada :
Tegaful製剤S-1とsiRNA含有liposomeの併用による新規がん治療法の開発,
アンチセンス・遺伝子・デリバリーシンポジウム2011, Sep. 2011.
103. Yosuke Hashimoto, Yumi Uehara, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNAリポプレックス投与時のTLR刺激が及ぼすanti-PEGIgM分泌誘導への影響,
アンチセンス・遺伝子・デリバリーシンポジウム2011, Sep. 2011.
104. Takuya Suzuki, 兵頭 健治, 山本 栄一, Masako Ichihara, Tatsuhiro Ishida, Hiroshi Kiwada, 石原 比呂之 and 菊池 寛 :
抗がん剤封入PEG 修飾リポソームにおけるABC 現象(第3報):イヌ,サルの検討,
第27回日本DDS学会学術集会, Jun. 2011.
105. Masako Ichihara, Ami Imoto, Yuki Hashiguchi, Risako Fujita, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソーム投与マウス脾臓中の抗PEG IgM分泌担当細胞の探索,
第27回日本DDS学会学術集会, Jun. 2011.
106. 兵頭 健治, Takuya Suzuki, 山本 栄一, Masako Ichihara, Tatsuhiro Ishida, Hiroshi Kiwada, 石原 比呂之 and 菊池 寛 :
抗がん剤封入PEG修飾リポソームにおけるABC現象(第4報):種差の検討,
第27回日本DDS学会学術集会, Jun. 2011.
107. Yosuke Hashimoto, Naoto Moriyoshi, Yumi Uehara, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNA含有PEG修飾ナノキャリアによるanti-PEG IgM 誘導におけるトール様受容体(TLR)の関与,
第27回日本DDS学会学術集会, Jun. 2011.
108. Takuya Suzuki, 兵頭 健治, 山本 栄一, Masako Ichihara, Tatsuhiro Ishida, Hiroshi Kiwada, 石原 比呂之 and 菊池 寛 :
抗がん剤封入PEG修飾リポソームにおけるABC現象(第2報):サルにおける検討,
日本薬剤学会第26年会, May 2011.
109. Hiroyuki Nakamura, Yusuke Doi, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1併用条件下でのPEG修飾リポソームの腫瘍内分布における投与間隔の影響,
日本薬学会第131年会, Mar. 2011.
110. 松永 真理子, Kazuya Nakamura, Naoto Moriyoshi, Tatsuhiro Ishida and Hiroshi Kiwada :
Tegafur製剤S-1とsiRNA含有リポソームの組み合わせによる新規がん治療戦略,
日本薬学会第131年会, Mar. 2011.
111. Takahiro Iwaki, Tatsuaki Tagami, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
リアルタイムRT-PCR及び共焦点顕微鏡を用いたsiRNAの細胞内動態評価,
日本薬学会第131年会, Mar. 2011.
112. Yumi Uehara, Tatsuaki Tagami, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
核酸含有PEG修飾ナノキャリアによるTLR刺激が及ぼすanti-PEGIgM分泌誘導への影響,
日本薬学会第131年会, Mar. 2011.
113. Tatsuhiro Ishida and Hiroshi Kiwada :
腫瘍内微小環境変化を利用したsiRNAデリバリーシステムの開発,
第32回生体膜と薬物の相互作用シンポジウム, Nov. 2010.
114. Hiroyuki Nakamura, Yusuke Doi, Ai Nagao, Haruna Matsumoto, Tomoko Okada, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームの腫瘍内分布における投与間隔の影響,
第49回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2010.
115. Mizuno Kitagawa, Takahiro Iwaki, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
細胞内導入後のsiRNA量の経時的変化に関する検討,
第49回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2010.
116. Ai Nagao, Masako Ichihara, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
抗PEG IgM抗体誘導におけるS-1とl-OHP封入PEG修飾リポソーム併用条件が与える影響の検討,
第49回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2010.
117. Ami Imoto, Masako Ichihara, Yuki Hashiguchi, Yumi Uehara, Tatsuhiro Ishida and Hiroshi Kiwada :
正常マウス脾臓細胞移入SCID マウスにおけるABC現象の再現,
第49回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2010.
118. Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
REG修飾ナノキャリア生体内投与後に生ずる免疫活性化(ABC現象)機構解明に関する検討,
第19回DDSカンファランス, Sep. 2010.
119. Tatsuhiro Ishida, Tatsuaki Tagami, Yumi Uehara, Naoto Moriyoshi, Takahiro Iwaki and Hiroshi Kiwada :
リポソームを用いた腫瘍へのsiRNAデリバリーシステムの開発,
遺伝子・デリバリー研究会第10回夏季セミナー, Sep. 2010.
120. Ai Nagao, Masako Ichihara, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1とl-OHP封入PEG修飾リポソームの併用条件下における抗PEGIgM抗体分泌の検討,
ナノライフサイエンス・オープンセミナー2010, Aug. 2010.
121. Mizuno Kitagawa, Takahiro Iwaki, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
トランスフェクション後の細胞内siRNA量の経時変化に関する検討,
ナノライフサイエンス・オープンセミナー2010, Aug. 2010.
122. Ami Imoto, Masako Ichihara, Yuki Hashiguchi, Yumi Uehara, Tatsuhiro Ishida and Hiroshi Kiwada :
正常マウス脾臓細胞移入SCIDマウスにおける抗PEG-IgM分泌に関する検討,
ナノライフサイエンス・オープンセミナー2010, Aug. 2010.
123. Takahiro Iwaki, Kazuya Nakamura, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNA-lipoplexへのPEG修飾がRNAi効果発現に与える影響,
ナノライフサイエンス・オープンセミナー2010, Aug. 2010.
124. Yumi Uehara, Tatsuaki Tagami, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
ナノ粒子ポリマー修飾剤の構造の違いが与える抗ポリマーIgMの分泌機構への影響に関する検討,
ナノライフサイエンス・オープンセミナー2010, Aug. 2010.
125. Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
RPG修飾リポソーム投与時に惹起されるABC現象に関する研究,
ナノライフサイエンス・オープンセミナー2010, Aug. 2010.
126. Masako Ichihara, Ami Imoto, Yuki Hashiguchi, Yumi Uehara, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソーム投与により誘導される抗PEG IgM分泌における脾臓の役割に関する検討,
第26回日本DDS学会, Jun. 2010.
127. Yuki Hashiguchi, Taro Shimizu, Masako Ichihara, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームに対する抗PEG-IgM分泌における脾臓辺縁帯B細胞の関与について,
第26回日本DDS学会, Jun. 2010.
128. Naoto Moriyoshi, Kazuya Nakamura, 松永 真理子, Tatsuhiro Ishida and Hiroshi Kiwada :
テガフール製剤S-1とBcl-2標的siRNA封入liposomeの併用療法によるがん治療の有用性に関する検討,
第26回日本DDS学会, Jun. 2010.
129. Mariko Matsunaga, Kazuya Nakamura, Naoto Moriyoshi, Tatsuhiro Ishida and Hiroshi Kiwada :
腫瘍移行性向上を目指したsiRNA-lipoplexの改良と評価,
遺伝子・デリバリー研究会第10回シンポジウム, Jun. 2010.
130. Takahiro Iwaki, Tatsuaki Tagami, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
Lipoplexのエンドソーム/ライソソームからの脱出メカニズムに関する検討,
遺伝子・デリバリー研究会第10回シンポジウム, Jun. 2010.
131. Tatsuhiro Ishida and Hiroshi Kiwada :
核酸デリバリーにおけるABC現象,
遺伝子・デリバリー研究会第10回シンポジウム, Jun. 2010.
132. Yumi Uehara, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
核酸デリバリーにおける修飾剤種が与えるポリマー特異性IgM分泌への影響,
遺伝子・デリバリー研究会第10回シンポジウム, Jun. 2010.
133. Masako Ichihara, Ami Imoto, Yuki Hashiguchi, Yumi Uehara, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソーム投与マウス脾臓の抗PEG IgM分泌における役割,
日本薬剤学会第25年会, May 2010.
134. Lila Selim Ahmed Ali Abu Amr, Yusuke Doi, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor,
日本薬剤学会第25年会, May 2010.
135. Yusuke Doi, Haruna Matsumoto, Tomoko Okada, Tatsuhiro Ishida and Hiroshi Kiwada :
ナノキャリアに対するEPR効果に寄与する腫瘍内微小環境変化に関する研究:S-1の低用量頻回投与(metronomic chemotherapy)から得られた知見,
日本薬学会第130年会, Mar. 2010.
136. Takahiro Iwaki, Tatsuaki Tagami, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
RNAi効果発現に対するLipoplexへのPEG修飾の影響に関する検討,
日本薬学会第130年会, Mar. 2010.
137. Yuki Hashiguchi, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象における抗PEG-IgM分泌とMZ-B細胞の活性化について,
日本薬学会第130年会, Mar. 2010.
138. Yumi Uehara, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象回避を目的としたlipoplexに対するpolymer修飾剤polyglycerolの有効性評価,
日本薬学会第130年会, Mar. 2010.
139. Kazuya Nakamura, Mariko Matsunaga, Takahiro Iwaki, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
テガフール製剤S-1とBcl-2標的siRNA封入リポソームの併用によるdouble modulation therapyの有用性,
日本薬学会第130年会, Mar. 2010.
140. Haruna Matsumoto, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
がん細胞種が及ぼす抗がん剤封入リポソームの腫瘍移行性とその治療効果への影響,
日本薬学会第130年会, Mar. 2010.
141. Takahiro Iwaki, Shinji Kizuki, Kazuya Nakamura, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
LipoplexのPEG修飾による細胞内取り込み量の変化及びRNAi効果に与える影響に関する検討,
第48回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2009.
142. Haruna Matsumoto, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
がん細胞種の違いが及ぼすPEG修飾リポソームの腫瘍移行及び分布への影響,
第48回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2009.
143. Tomoko Okada, 土井 祐輔, Lila Selim Ahmed Ali Abu Amr, Tatsuhiro Ishida and Hiroshi Kiwada :
フッ化ピリミジン系経口抗癌剤とOxaliplatin封入PEG修飾カチオニックリポソーム併用による抗腫瘍効果の検討,
第48回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2009.
144. Yuki Hashiguchi, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象の要因とされる抗PEG-IgMの分泌と脾臓辺縁帯B細胞の活性化の関係について,
第48回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2009.
145. Yumi Uehara, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象回避を目的としたポリグリセロール修飾リポプレックスの有効性評価,
第48回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2009.
146. Kazuya Nakamura, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNAによるBcl-2遺伝子ノックダウンとS-1のメトロノミック療法の組み合わせによる相乗的な制がん効果,
第68回日本癌学会学術総会, Oct. 2009.
147. Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1のmetronomic chemotherapyがもたらすナノキャリア腫瘍集積性向上に関わる腫瘍内微小環境変化,
第68回日本癌学会学術総会, Oct. 2009.
148. Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
PEGを用いた核酸送達システムにおいて核酸がanti-PEG IgM分泌に与える影響,
第18回DDSカンファレンス, Sep. 2009.
149. Yusuke Doi, Tomoko Okada, Haruna Matsumoto, Tatsuhiro Ishida and Hiroshi Kiwada :
ナノキャリアに対するEPR効果に寄与する腫瘍内微小環境変化に関する検討:S-1の低用量頻回投与(metronomic chemotherapy)から得られた知見,
第18回DDSカンファレンス, Sep. 2009.
150. Kazuya Nakamura, Mariko Matsunaga, Takuya Suzuki, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
Argonaute2標的siRNAの全身投与による制がん効果及び毒性の検討,
遺伝子・デリバリー研究会第9回シンポジウム, Jul. 2009.
151. Tatsuaki Tagami, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNA封入PEG修飾リポソーム投与時におけるsiRNA配列のanti-PEG IgM分泌に与える影響,
遺伝子・デリバリー研究会第9回シンポジウム, Jul. 2009.
152. 木元 歩, 石原 務, 古林 千沙, 高崎 奈央子, 水島 徹, 檜垣 恵, 水島 裕, Tatsuhiro Ishida and Hiroshi Kiwada :
ABC現象回避を目的としたステルス型ナノ粒子製剤の開発,
第25回日本DDS学会, Jul. 2009.
153. Lila Selim Ahmed Ali Abu Amr, Shinji Kizuki, Yusuke Doi, Takuya Suzuki, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via dual-targeting approach in a murine solid tumor model,
第25回日本DDS学会, Jul. 2009.
154. Tatsuaki Tagami, Kazuya Nakamura, Taro Shimizu, Naoshi Yamazaki, Tatsuhiro Ishida and Hiroshi Kiwada :
ポリエチレングリコール(PEG)を利用した核酸送達システムにおいてプラスミドDNA配列内のCpG除去が抗PEG抗体産生に与える影響,
第25回日本DDS学会, Jul. 2009.
155. Kazuya Nakamura, Mariko Matsunaga, Takuya Suzuki, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
Argonaute2遺伝子を標的としたsiRNAによるがん治療法の有用性と安全性,
第25回日本DDS学会, Jul. 2009.
156. Mariko Matsunaga, Kazuya Nakamura, Tatsuhiro Ishida and Hiroshi Kiwada :
腫瘍移行性向上を目指したsiRNA-lipoplexの改良とその評価,
第25回日本DDS学会, Jul. 2009.
157. Yuki Hashiguchi, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソームによる抗PEG-IgMの誘導と脾臓辺緑体B細胞の活性化の関係に関する検討,
第25回日本DDS学会, Jul. 2009.
158. Takeshima Hidemi, Takuya Suzuki, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
In vivo imagingを利用したリポソームの腫瘍移行性の評価,
第25回日本DDS学会, Jul. 2009.
159. Tatsuhiro Ishida and Hiroshi Kiwada :
核酸デリバリーにおける accelerated blood clearance (ABC)現象,
第25回日本DDS学会, Jul. 2009.
160. Tatsuhiro Ishida, 浅井 知浩, 奥 直人 and Hiroshi Kiwada :
Argonaute2標的siRNAリポプレックスを用いたがん治療戦略,
日本薬剤学会第24年会 学術シンポジウム4 RNAi医薬の展望 –From Bench to Bedside -, May 2009.
161. Mariko Matsunaga, Kazuya Nakamura, Takuya Suzuki, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
フッ化ピリミジン系経口抗がん剤併用によるsiRNA-lipoplexの腫瘍移行向上の試み,
日本薬剤学会第24年会, May 2009.
162. Lila Selim Ahmed Ali Abu Amr, Takuya Suzuki, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin targeting to angiogenic vessels by PEG-coated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.,
日本薬剤学会第24年会, May 2009.
163. Shinji Kizuki, Tatsuaki Tagami, Michi Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNAリポプレックスのエンドソーム脱出ならびにキャリアからのsiRNA解離過程の評価,
日本薬学会第129年会, Mar. 2009.
164. Takuya Suzuki, Kazuya Nakamura, Mariko Matsunaga, Tatsuaki Tagami, 浅井 知浩, Tatsuhiro Ishida, 奥 直人 and Hiroshi Kiwada :
Argonaute2標的siRNAによる腫瘍新生血管傷害療法の試み,
日本薬学会第129年会, Mar. 2009.
165. Taro Shimizu, Hiroaki Kato, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾リポソーム投与による脾臓辺縁帯B細胞の活性化,
日本薬学会第129年会, Mar. 2009.
166. Ayumi Hagi, Yusuke Doi, Yurie Hira, Tatsuhiro Ishida and Hiroshi Kiwada :
Oxaliplatin (1-OHP) 封入PEG修飾cationic liposomeによる抗腫瘍効果の検討,
日本薬学会第129年会, Mar. 2009.
167. Kaori Shimoda, Kazutaka Atobe, 浅井 知浩, Tatsuhiro Ishida, 菊池 寛, 奥 直人 and Hiroshi Kiwada :
MT1-MMPを標的とした腫瘍細胞及び腫瘍新生血管ダブルターゲティングリポソームの開発に関する検討,
日本薬学会第129年会, Mar. 2009.
168. Yusuke Doi, Yurie Hira, Tatsuhiro Ishida and Hiroshi Kiwada :
フッ化ピリミジン系経口抗癌剤S-1のmetronomic chemotherapyとoxaliplatin (1-OHP) 封入リポソーム併用療法の開発:本併用療法がもたらす 1-OHP腫瘍移行性向上に関する検討,
日本薬学会第129年会, Mar. 2009.
169. Tatsuaki Tagami, Kazuya Nakamura, Taro Shimizu, Naoshi Yamazaki, Tatsuhiro Ishida and Hiroshi Kiwada :
CpG-free pDNAを使用したPEG修飾リポプレックス投与がABC現象に与える影響,
日本薬学会第129年会, Mar. 2009.
170. 小出 裕之, 畑中 剣太朗, 浅井 知浩, Tatsuhiro Ishida, Hiroshi Kiwada, 横山 昌幸 and 奥 直人 :
PEG修飾ナノキャリアー頻回投与によるABC現象の機構解明,
日本薬学会第129年会, Mar. 2009.
171. Kazuya Nakamura, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
Argonaute2標的siRNA細胞内導入による細胞増殖抑制効果∼細胞種による違い∼,
日本薬学会第129年会, Mar. 2009.
172. Michi Shimizu, Tatsuaki Tagami, Shinji Kizuki, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNAリポプレックスによる細胞内取り込み量及び遺伝子サイレンシング効果の経時的変化に関する検討,
第47回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2008.
173. Masayoshi Abe, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG化リポソーム投与による抗PEG-lgMの発想と精製法の研究,
第47回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2008.
174. takeshima hidemi, Tatsuhiro Ishida and Hiroshi Kiwada :
REG修飾リポソームの体内動態に及ぼす内封ドキソルビシンの影響,
第47回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2008.
175. Yurie Hira, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
フッ化ピリミジン系抗がん剤とOxaliplatin(l-OHP)封入リポソーム併用療法に関する研究:l-OHP放出性の違いが効果と毒性に及ぼす影響,
第47回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2008.
176. Mariko Matsunaga, Takuya Suzuki, Kazuya Nakamura, Yusuke Doi, Tatsuhiro Ishida and Hiroshi Kiwada :
フッ化ピリミジン系経口抗がん剤併用によるsiRNA-lipoplexの腫瘍移行向上の試み,
第47回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2008.
177. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
ナノキャリアの生体反応性とバイオ応用に関する研究,
日本薬物動態学会第23回年会, Nov. 2008.
178. Yusuke Doi, Yurie Hira, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1 metronomic chemotherapy とオキサリプラチン封入ナノキャリア併用療法の開発:相乗的効果増強機構の解明に関する研究,
第46回日本癌治療学会総会, Oct. 2008.
179. Tatsuaki Tagami, Tatsuhiro Ishida, 奥 直人 and Hiroshi Kiwada :
PEG修飾カチオニックリポソームを用いたArgonaute 2-siRNAによる抗腫瘍効果,
第67回日本癌学会学術総会, Oct. 2008.
180. Yusuke Doi, Yurie Hira, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1を用いたMetronomic chemotherapyによって生じる腫瘍内微小環境の変化がもたらすリポソームの腫瘍内移行性の向上,
第17回DDSカンファランス, Sep. 2008.
181. Kazuya Nakamura, Takuya Suzuki, Yusuke Doi, Mariko Matsunaga, Tatsuaki Tagami, 浅井 知浩, Tatsuhiro Ishida, 奥 直人 and Hiroshi Kiwada :
Argonaute2標的siRNAとフッ化ピリミジン系経口抗がん剤の併用療法によるin vivo抗腫瘍効果の検討,
第17回DDSカンファランス, Sep. 2008.
182. Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
投与量逆依存的なABC現象発現と脾臓B細胞活性化との相関に関する検討,
第17回DDSカンファランス, Sep. 2008.
183. Tatsuaki Tagami, Kazuya Nakamura, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾siRNA-lipoplex投与時におけるanti-PEG IgM分泌に対するsiRNAの影響,
第30回生体膜と薬物の相互作用シンポジウム, Aug. 2008.
184. 小出 裕之, 浅井 知浩, 畑中 剣太朗, Tatsuhiro Ishida, Hiroshi Kiwada, 横山 昌幸 and 奥 直人 :
ナノキャリア頻回投与時におけるABC現象の機構解明,
第24回日本DDS学会, Jun. 2008.
185. Taro Shimizu, Kousuke Nawata, 吉岡 靖雄, Tatsuhiro Ishida, 中川 晋作 and Hiroshi Kiwada :
PEG修飾タンパクおよびPEG修飾アデノウイルス投与による抗PEG IgM誘導に関する検討,
第24回日本DDS学会, Jun. 2008.
186. Takuya Suzuki, Kazuya Nakamura, Tatsuaki Tagami, Kiyomi Hirose, Jose Mario Barichello, 浅井 知浩, Tatsuhiro Ishida, 奥 直人 and Hiroshi Kiwada :
Argonaute2 (Ago2)標的siRNA-lipoplexを用いたin vivo抗腫瘍効果,
第24回日本DDS学会, Jun. 2008.
187. Kazuya Nakamura, Takuya Suzuki, Tatsuaki Tagami, Jose Mario Barichello, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNA―カチオニックリポソーム複合体の表面荷電が新生血管親和性に及ぼす影響,
第24回日本DDS学会, Jun. 2008.
188. Kazuya Nakamura, Takuya Suzuki, Tatsuaki Tagami, Jose Mario Barichello, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNA-カチオニックリポソーム複合体の新生血管親和性向上の要因の解明に関する研究,
日本薬剤学会第23年会, May 2008.
189. Taro Shimizu, Kousuke Nawata, Kazushige Naruke, Tatsuhiro Ishida and Hiroshi Kiwada :
ポリエチレングリコール修飾タンパク投与による抗PEG IgM誘導に関する研究,
日本薬剤学会第23年会, May 2008.
190. Shinji Kizuki, Jose Mario Barichello, Tatsuaki Tagami, 菊池 寛, Tatsuhiro Ishida and Hiroshi Kiwada :
siRNAリポプレックスの新規調製法がもたらす細胞内取り込み機構の変化及びRNAi効果に与える影響に関する研究,
日本薬剤学会第23年会, May 2008.
191. Yusuke Doi, Yurie Hira, Tatsuhiro Ishida and Hiroshi Kiwada :
S-1を用いたlow dose chemotherapyによって生ずる腫瘍内微少環境の変化が与えるリポソームの腫瘍内動態変化に関する検討,
日本薬剤学会第23年会, May 2008.
192. Ayumi Hagi, Tatsuaki Tagami, Tatsuhiro Ishida and Hiroshi Kiwada :
がん細胞およびがん新生血管に親和性を有するPEG修飾Cationic liposomeの開発に関する検討,
日本薬剤学会第23年会, May 2008.
193. Kaori Shimoda, Kazutaka Atobe, 浅井 知浩, Tatsuhiro Ishida, 菊池 寛, 奥 直人 and Hiroshi Kiwada :
抗がん剤リポソーム製剤化検討」資料収集および「腫瘍細胞および腫瘍新生血管を標的とした抗MT1-MMP抗体修飾リポソームの有用性に関する検討,
日本薬剤学会第23年会, May 2008.
194. Takuya Suzuki, Kazuya Nakamura, Tatsuaki Tagami, Kiyomi Hirose, M J Barichello, 浅井 知浩, Tatsuhiro Ishida, 菊池 寛, 奥 直人 and Hiroshi Kiwada :
Argonaute2(Ago2)標的siRNA腫瘍内直接投与による抗がん効果の検討,
日本薬剤学会第23年会, May 2008.
195. Tatsuaki Tagami, Kazuya Nakamura, Taro Shimizu, Tatsuhiro Ishida and Hiroshi Kiwada :
PEG修飾siRNAリポプレックス投与時におけるanti-PEG IgM分泌に関する検討,
日本薬剤学会第23年会, May 2008.
196. Taisuke Matsuo, Naoshi Yamazaki, 新山 加菜美, Takenori Yamamoto, Tatsuhiro Ishida, Hiroshi Kiwada, Masatoshi Kataoka and Yasuo Shinohara :
タグを付加したPf3 coat protein変異体の調製およびリポソームとの相互作用の解析,
Mar. 2008.
197. Tatsuhiro Ishida and Hiroshi Kiwada :
ポリエチレングリコール修飾リポソーム投与時に生ずるaccelerated blood clearance (ABC)現象,
日本薬学会第127年会,シンポジウムS6, Mar. 2007.
198. 森岡 由美, 原島 秀吉, 吉村 耕二, Hiroshi Kiwada, Masayuki Shono and 吉村 哲郎 :
リポソームと細胞内運命とその制御機構に関する研究,
第17回生体膜と薬物の相互作用シンポジウム, 1995.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

  • Improvement of tumor-targeting therapy with nanocarrier system by changing the tumor microenvironment. (Project/Area Number: 24390010 )
  • Development of novel vaccine system with nanocarrier (Project/Area Number: 23659082 )
  • Anti-PEG Immunity upon nucleic acid delivery (Project/Area Number: 23390012 )
  • Evaluation on EPR effect and active control of EPR effect for achieving efficient tumor accumulation of nanocarrier delivery system (Project/Area Number: 21689002 )
  • Study for Interaction of Biological Milieu with Nano-drug Carrier system (Project/Area Number: 20390013 )
  • 腫瘍内微小環境変化を利用した新規DDSの開発 (Project/Area Number: 20015033 )
  • がん新生血管を標的とした機能性リポソームによる革新的治療法の開発 (Project/Area Number: 18015036 )
  • Introduction of tyrosine hydroxylase gene into the cells from brain for the treatment of parkinson's disease. (Project/Area Number: 11672264 )
  • Research for development of nobel type vaccine with cetylmanoside-modified liposomes (Project/Area Number: 11557194 )
  • Effects of Ascorbic Acid on the Metabolic Fate and the Hepatitis of Hydrazine Derivatives (Project/Area Number: 05671899 )
  • Uptake mechanism and intracellular destiny of liposomes in RES (Project/Area Number: 05671783 )
  • Development of intracellular drug delivery system utilizing liposomes (Project/Area Number: 02670981 )
  • Search by Researcher Number (50120184)